var title_f5_58_6048="Thumb spica cast 2";
var content_f5_58_6048=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Thumb spica cast: Step 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 207px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Place a stockinette or similar material over the hand and forearm. Minimize wrinkles as much as possible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_58_6048=[""].join("\n");
var outline_f5_58_6048=null;
var title_f5_58_6049="Irving tubal ligation D";
var content_f5_58_6049=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Irving tubal ligation D",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_58_6049=[""].join("\n");
var outline_f5_58_6049=null;
var title_f5_58_6050="Patient information: Bird flu (avian influenza) (The Basics)";
var content_f5_58_6050=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?32/47/33522\">",
"         Patient information: Flu (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/61/11217\">",
"         Patient information: Psittacosis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?38/12/39105\">",
"         Patient information: Influenza prevention (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/12/35013\">",
"         Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Bird flu (avian influenza) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/bird-flu-avian-influenza-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H9361451\">",
"      <span class=\"h1\">",
"       What is bird flu?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Bird flu (also known as &ldquo;avian influenza&rdquo;) is a type of flu that normally happens in birds. But in rare cases, it has spread from infected birds to humans. Even though bird flu is rare in humans, when it does happen it is usually severe. Children and young adults seem to be more likely than older people to get bird flu.",
"     </p>",
"     <p>",
"      An outbreak of bird flu caused illness in 18 people in Hong Kong in 1997. Since then, a few cases have happened in Asia, the Middle East, and Africa. Most people who have gotten bird flu were around sick or dead birds in the week before they got sick. Scientists think that people who get bird flu usually get it from sick birds. But if the virus that causes bird flu changes or &ldquo;mutates,&rdquo; it might become possible for bird flu to be passed from one person to another.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361466\">",
"      <span class=\"h1\">",
"       What are the most common symptoms of bird flu?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptoms of bird flu include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever (temperature higher than 100&ordm;F or 37.8&ordm;C)",
"       </li>",
"       <li>",
"        Cough",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Diarrhea",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other symptoms might include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling confused",
"       </li>",
"       <li>",
"        Sore throat",
"       </li>",
"       <li>",
"        Headache or body aches",
"       </li>",
"       <li>",
"        Runny nose",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361481\">",
"      <span class=\"h1\">",
"       Is bird flu dangerous?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, bird flu can be very dangerous. It can cause severe illness. More than half of the people who get bird flu die. People with bird flu are much more likely to have severe illness and to die than people with seasonal flu.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361496\">",
"      <span class=\"h1\">",
"       How can I protect myself from bird flu?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In general, it&rsquo;s a good idea to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wash your hands often with soap and water or alcohol hand rubs.",
"       </li>",
"       <li>",
"        Stay away from sick people or animals.",
"       </li>",
"       <li>",
"        Stay away from chickens and other birds in countries where there are outbreaks of bird flu. This includes markets that sell live birds.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361513\">",
"      <span class=\"h1\">",
"       What should I do if I get symptoms of bird flu?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor of nurse right away if you have been around sick or dead birds or have traveled in a country that has had cases of bird flu. Do not leave your house unless your doctor or nurse tells you to go to a clinic or hospital. Many people with bird flu need to be in the hospital.",
"     </p>",
"     <p>",
"      While you are at home, rest and drink plenty of fluids. You can also take",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      &nbsp;(sample brand name: Tylenol&reg;) to relieve fever and aches.",
"     </p>",
"     <p>",
"      Do not give",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"       aspirin",
"      </a>",
"      or medicines that contain aspirin to children younger than 18. In children, aspirin can cause a serious problem called Reye syndrome.",
"     </p>",
"     <p>",
"      Take your child to the doctor if he or she:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Starts breathing fast or has trouble breathing",
"       </li>",
"       <li>",
"        Starts to turn blue or purple",
"       </li>",
"       <li>",
"        Is not drinking enough fluids",
"       </li>",
"       <li>",
"        Will not wake up or doesn&rsquo;t react to you",
"       </li>",
"       <li>",
"        Is so fussy that he or she does not want to be held",
"       </li>",
"       <li>",
"        Gets better from the flu but then gets sick again with a fever or cough",
"       </li>",
"       <li>",
"        Has a fever with a rash",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you go to a walk-in clinic or a hospital because you think you have bird flu, tell someone right away why you are there. The staff will ask you to wear a mask or to wait somewhere where you are less likely to spread your infection.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361530\">",
"      <span class=\"h1\">",
"       Can bird flu be treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, people with bird flu usually get medicines called &ldquo;anti-viral medicines.&rdquo; These medicines can help people avoid some of the problems caused by bird flu. Antibiotics DO NOT WORK on the flu.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361547\">",
"      <span class=\"h1\">",
"       What if I am pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Any kind of flu can be very dangerous for pregnant women. If you are pregnant, it is very important that you get vaccinated against seasonal flu. You should also avoid taking care of anyone who has the flu.",
"     </p>",
"     <p>",
"      If you are pregnant, call your doctor or nurse right away if:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        You might have been near someone with the flu.",
"       </li>",
"       <li>",
"        You think you might be coming down with the flu. In pregnant women, the symptoms of the flu can get worse very quickly. The flu can even cause trouble breathing or lead to death of the woman or her baby. That is why it is so important to talk to doctor or nurse as soon as you notice any flu symptoms.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361564\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=see_link\">",
"       Patient information: Flu (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/61/11217?source=see_link\">",
"       Patient information: Psittacosis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=see_link\">",
"       Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/12/39105?source=see_link\">",
"       Patient information: Influenza prevention (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?5/58/6050?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83059 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-C38B34FA94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_58_6050=[""].join("\n");
var outline_f5_58_6050=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361451\">",
"      What is bird flu?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361466\">",
"      What are the most common symptoms of bird flu?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361481\">",
"      Is bird flu dangerous?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361496\">",
"      How can I protect myself from bird flu?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361513\">",
"      What should I do if I get symptoms of bird flu?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361530\">",
"      Can bird flu be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361547\">",
"      What if I am pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361564\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/12/39105?source=related_link\">",
"      Patient information: Influenza prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=related_link\">",
"      Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/61/11217?source=related_link\">",
"      Patient information: Psittacosis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_58_6051="Marsupialization Bartholin cyst";
var content_f5_58_6051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Marsupialization of Bartholin gland cyst or abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 462px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A vertical oval incision is made over the center of the cyst/abscess where it protrudes at the vestibule and outside the hymenal ring. The cyst cavity can be irrigated with saline solution and loculations can be broken up with a hemostat, as needed. The cyst wall is then everted and sutured onto the edge of the vestibular mucosa with interrupted 2-0 absorbable suture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_58_6051=[""].join("\n");
var outline_f5_58_6051=null;
var title_f5_58_6052="Ganciclovir (ophthalmic): Pediatric drug information";
var content_f5_58_6052=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ganciclovir (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?6/5/6228?source=see_link\">",
"    see \"Ganciclovir (ophthalmic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/53/41811?source=see_link\">",
"    see \"Ganciclovir (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8106936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vitrasert&reg;;",
"     </li>",
"     <li>",
"      Zirgan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10501470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/5/6228?source=see_link\">",
"      see \"Ganciclovir (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      CMV retinitis:",
"     </b>",
"     Sustained release intravitreal implant:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;9 years: One implant for 5- to 8-month period; following depletion of ganciclovir, as evidenced by progression of retinitis, implant may be removed and replaced",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: One implant for 5- to 8-month period; following depletion of ganciclovir, as evidenced by progression of retinitis, implant may be removed and replaced",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Herpetic keratitis:",
"     </b>",
"     Ophthalmic gel: Children &ge;2 years and Adults: Apply 1 drop in affected eye 5 times/day (approximately every 3 hours while awake) until corneal ulcer heals, then 1 drop 3 times/day for 7 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8107063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zirgan&reg;: 0.15% (5 g) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Implant, intravitreal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vitrasert&reg;: 4.5 mg (1s) [released gradually over 5-8 months]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8106939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13271513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic gel: Gel is intended for topical ophthalmic use only.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13271505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intravitreal implant: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from freezing, excessive heat, and light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ophthalmic gel: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); do not freeze.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10501464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intravitreal implant: Treatment of CMV retinitis in patients with AIDS (FDA approved in ages &ge;9 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic gel: Treatment of acute herpetic keratitis (dendritic ulcers) (FDA approved in ages &ge;2 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8106933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ganciclovir may be confused with acyclovir",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8106978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intravitreal implant",
"     </b>",
"     : Ocular: Visual acuity decreased (&ge;3 lines; temporary).",
"     <b>",
"      Note:",
"     </b>",
"     Adverse reactions are likely a result of the surgical implant procedure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ophthalmic gel:",
"     </b>",
"     Ocular: Blurred vision, conjunctival hyperemia, irritation, punctate keratitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10501465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ganciclovir, acyclovir, or any component; intravitreal implant: Any clinical condition contraindicating intraocular surgery, such as external infection or severe thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10501467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in children because long-term safety has not been determined and because of the potential long-term carcinogenic and adverse reproductive effects of ganciclovir.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10501466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intravitreal implant: Following implantation, immediate and temporary decrease in visual acuity will be seen for 2-4 weeks; does not treat systemic CMV infection; monitor patients for signs and symptoms of systemic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gel formulation: Contact lenses should not be worn during therapy (or in any patient with herpetic keratitis); formulation is intended for topical ophthalmic use only.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8106981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8106956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8106957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies conducted with systemic ganciclovir. Based on animal studies, a U.S. Boxed Warning has been added to the labeling of the systemic product and effective contraception is recommended in males and females using systemic therapy. The amount of ganciclovir available systemically following topical application of the Zirgan&reg; ophthalmic gel is significantly less in comparison I.V. doses (0.1%). Vitrasert&reg; intravitreal implant contains only 4.5-6.4 mg of ganciclovir and is released locally in the vitreous from the implant. Ophthalmic formulations should be used only if potential benefit justifies the risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10503159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ganciclovir is phosphorylated to a substrate which competitively inhibits the binding of deoxyguanosine triphosphate to DNA polymerase; ganciclovir triphosphate competes with deoxyguanosine triphosphate for incorporation into viral DNA and interferes with viral DNA chain elongation, resulting in inhibition of viral replication",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13271512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Ophthalmic gel: Systemic absorption (0.1% in comparison to I.V. doses)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10503160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/53/41811?source=see_link\">",
"      see \"Ganciclovir (ophthalmic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mothers should discontinue breast-feeding while on ganciclovir therapy. Ganciclovir is not a cure for CMV retinitis. Regular follow-up ophthalmologic exams are necessary. For ophthalmic gel use: Avoid contamination of the applicator tip; contact physician and discontinue use if redness, swelling, pain, or irritation persists. Contact lenses should not be worn while using this product.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations From CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/58/6052/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15993 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-4C9EBFD82E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_58_6052=[""].join("\n");
var outline_f5_58_6052=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106936\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501470\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107063\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106939\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13271513\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13271505\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501464\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106933\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106978\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501465\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501467\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501466\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299386\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106981\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106956\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106957\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503159\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13271512\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503160\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15993\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15993|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/5/6228?source=related_link\">",
"      Ganciclovir (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/53/41811?source=related_link\">",
"      Ganciclovir (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/3/24630?source=related_link\">",
"      Ganciclovir (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/18/31012?source=related_link\">",
"      Ganciclovir (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/42/13990?source=related_link\">",
"      Ganciclovir (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_58_6053="Ephedrine (systemic): Patient drug information";
var content_f5_58_6053=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ephedrine (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/14/11493?source=see_link\">",
"     see \"Ephedrine (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/10/37029?source=see_link\">",
"     see \"Ephedrine (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10031090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691934",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ephedrine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703545",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A fast heartbeat, high blood pressure, or narrow angle glaucoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with problems passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle, vein, or into the fatty part of the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11668 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-C9F66847B9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_58_6053=[""].join("\n");
var outline_f5_58_6053=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031090\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031092\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031091\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031096\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031097\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031099\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031094\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031095\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031100\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031101\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/14/11493?source=related_link\">",
"      Ephedrine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/10/37029?source=related_link\">",
"      Ephedrine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_58_6054="Normal cc views";
var content_f5_58_6054=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Normal CC (craniocaudal) views of both breasts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 399px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    By convention, the mammograms of both breasts are viewed as mirror images. The upper half represents the lateral or outer aspect of the breast and the lower half represents the medial or inner aspect of the breast. The nipples are in profile and normal fat is visible between the edge of the film and the glandular tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_58_6054=[""].join("\n");
var outline_f5_58_6054=null;
var title_f5_58_6055="Dirofilaria repens life cycle";
var content_f5_58_6055=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 584px\">",
"   <div class=\"ttl\">",
"    Dirofilaria repens life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 564px; height: 477px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During a blood meal, an infected mosquito (",
"    <em>",
"     Aedes",
"    </em>",
"    ,",
"    <em>",
"     Anopheles",
"    </em>",
"    ,",
"    <em>",
"     Culex",
"    </em>",
"    ,",
"    <em>",
"     Mansonia",
"    </em>",
"    ) introduces third-stage filarial larvae of",
"    <em>",
"     Dirofilaria repens",
"    </em>",
"    onto the skin of the canine definitive host (but also occasionally humans, especially in Europe), where they penetrate into the bite wound",
"    <strong>",
"     (1)",
"    </strong>",
"    . In the definitive host, the L3 larvae undergo two more molts into L4 and adults, the latter of which resides in subcutaneous tissues",
"    <strong>",
"     (2)",
"    </strong>",
"    . Adult females are usually 100 to 170 mm long by 460 to 650 micrometers wide; males are usually 50 to 70 mm long by 370 to 450 micrometers wide. Adults can live for 5 to 10 years. In subcutaneous tissue, the female worms are capable of producing microfilariae over their lifespan. The microfilariae are found in peripheral blood",
"    <strong>",
"     (3)",
"    </strong>",
"    . A mosquito ingests the microfilariae during a blood meal",
"    <strong>",
"     (4)",
"    </strong>",
"    . After ingestion, the microfilariae migrate from the mosquito's midgut through the hemocoel to the Malpighian tubules in the abdomen",
"    <strong>",
"     (5)",
"    </strong>",
"    . There the microfilariae develop into first-stage larvae",
"    <strong>",
"     (6)",
"    </strong>",
"    and subsequently into third-stage infective larvae",
"    <strong>",
"     (7)",
"    </strong>",
"    . The third-stage infective larvae migrate to the mosquito's proboscis",
"    <strong>",
"     (8)",
"    </strong>",
"    and can infect another definitive host when it takes a blood meal",
"    <strong>",
"     (1)",
"    </strong>",
"    . In humans",
"    <strong>",
"     (9)",
"    </strong>",
"    ,",
"    <em>",
"     D. repens",
"    </em>",
"    usually manifests as either a wandering worm in the subcutaneous tissue or a granulomatous nodule, although there are reports of pulmonary dirofilariasis with this species.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Filariasis. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/HTML/ImageLibrary/A-F/Filariasis/body_Filariasis_il23.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/HTML/ImageLibrary/A-F/Filariasis/body_Filariasis_il23.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_58_6055=[""].join("\n");
var outline_f5_58_6055=null;
var title_f5_58_6056="The adaptive cellular immune response";
var content_f5_58_6056=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The adaptive cellular immune response",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/58/6056/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/58/6056/contributors\">",
"     Francisco A Bonilla, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/58/6056/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/58/6056/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/58/6056/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/58/6056/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/58/6056/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cells regulate the activities of B cells, T cells, and other cells participating in immune responses. They provide help for antibody production by B cells, and they are also the effectors of antigen-specific cell-mediated immunity (CMI). CMI is important in the elimination of cells infected with pathogens that replicate intracellularly (eg, viruses, mycobacteria, and some bacteria) and cells exhibiting aberrant differentiation (eg, neoplasms). CMI also destroys allogeneic cells (graft rejection). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=see_link\">",
"     \"Transplantation immunobiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    T cell receptors (TCRs), in contrast to immunoglobulins (Ig), exist only as multimeric membrane-bound complexes and are not secreted intact in soluble form. Also unlike Ig, TCRs recognize fragments (peptides) of protein or glycoprotein antigens in complexes with major histocompatibility molecules on the surfaces of antigen presenting cells (APCs, also called accessory cells), or on targets of cytotoxicity. Note the distinction between the processed antigen (peptide) eliciting a response, and the major histocompatibility complex (MHC) antigen with which it becomes associated to stimulate peptide-specific T cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37733?source=see_link\">",
"     \"T cell receptor genetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cellular interactions that form the basis of CMI are discussed in this topic review. Related topics and T cell help for antibody production are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37733?source=see_link\">",
"     \"T cell receptor genetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTIGEN PRESENTING CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cell responses are initiated by APCs, which are reviewed briefly here and discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25432?source=see_link\">",
"     \"Antigen presenting cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dendritic cells (DCs) are the predominant class of \"professional\" antigen presenting cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/1\">",
"     1",
"    </a>",
"    ]. The main subtypes include plasmacytoid DCs (pDCs) and conventional DCs (cDCs). These are further divided into additional subtypes that have distinct surface marker expression, morphology, tissue distribution, and cytokine production and that lead to distinct pathways of T cell stimulation.",
"    <span class=\"nowrap\">",
"     Monocytes/macrophages",
"    </span>",
"    may also exert some APC activity, and monocytes may differentiate into DCs.",
"   </p>",
"   <p>",
"    Only APCs constitutively express MHC class II molecules (which are required for activation of CD4+ T cells) and display the necessary costimulatory signals. The great majority of somatic cells express MHC class I and can serve as targets of CD8+ cytotoxic T cells. Under certain circumstances, a variety of cell types can be induced to express MHC class II. However, they do",
"    <strong>",
"     not",
"    </strong>",
"    possess costimulatory activity.",
"   </p>",
"   <p>",
"    B cells express MHC class II molecules, which are required to receive T cell help. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    .) Although they are not competent to activate resting naive T cells, B cells may stimulate memory T cells (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Memory T cells'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism of presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a brief overview of the mechanism of antigen presentation. Dendritic cells utilize a system of receptors (pattern recognition receptors, examples being the \"toll-like\" receptors) that bind to a variety of microbial products, such as bacterial lipopolysaccharide. These receptors stimulate development and migration of immature dendritic cells in the periphery. Under the influence of cytokines and chemokines, dendritic cells mature and migrate into the secondary lymphoid tissues where they interact with T and B cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=see_link\">",
"     \"Toll-like receptors: Roles in disease and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dendritic cells are highly active in processing and presenting antigen to T cells. Antigen is taken up via several means (macropinocytosis, in immune complexes via IgG Fc receptors, etc); it is then degraded, and peptides are loaded onto MHC class I or class II molecules. Intracellular-derived antigens (intracellular self proteins or products of organisms that replicate intracellularly) are predominantly presented via MHC class I, and extracellular antigens mainly via class II. However, there is significant overlap in these pathways. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=see_link\">",
"     \"Major histocompatibility complex (MHC) structure and function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     T CELL ACTIVATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Structure of the T cell receptor CD3 complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The T cell receptor (TCR) alpha-beta (TCR2) or gamma-delta (TCR1) heterodimer is non-covalently associated with the CD3 complex on the cell membrane. CD3 is comprised of five subunits and is expressed on all T cells. The complex has a critical role in transducing a signal of TCR contact across the lymphocyte membrane (",
"    <a class=\"graphic graphic_figure graphicRef69555 \" href=\"UTD.htm?17/63/18421\">",
"     figure 1",
"    </a>",
"    ). The interaction of the TCR with a complementary complex of peptide+MHC forms the basis of the antigen specificity of T cell activation by APCs, and target cell recognition in CMI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     T cell accessory molecules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two co-receptor molecules, CD4 and CD8, have great importance for T cell development, and for antigen recognition and activation of mature T cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .) There are a host of additional cell surface molecules that play roles in T cell interactions with other cells: T cell activation by antigen presenting cells, T cell regulation of other T cells and B cells, and cytotoxic T cell killing. Some of these are adhesion molecules, others are mainly transducers of activating signals, and several have both functions. Some of these T cell accessory molecules are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef72603 \" href=\"UTD.htm?12/6/12396\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     T cell interactions and movements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the variety of signals involved in T cell interactions with other cells (",
"    <a class=\"graphic graphic_table graphicRef72603 \" href=\"UTD.htm?12/6/12396\">",
"     table 1",
"    </a>",
"    ), it is not yet certain in what temporal sequence these signals are all generated, nor which signals are absolutely required in a given circumstance, and which act exclusively as potentiators or inhibitors of activation. Both may be true of a particular signaling pathway, depending upon the mechanism of T cell activation.",
"   </p>",
"   <p>",
"    In this topic review, we will introduce models describing the complex process of CD4+ T cell transition from the resting to the activated state.",
"   </p>",
"   <p>",
"    Naive T cells reside in secondary lymphoid tissues, such as spleen, lymph nodes, and Peyer's patches in the intestine. Naive T cells rely upon the migration of dendritic cells into the lymphoid tissues to bring information about new immunological events occurring in peripheral tissues into the appropriate areas; within secondary lymphoid tissue, the naive T cells can \"scan\" the new information and possibly be activated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since naive T cells continually recirculate through the blood, spleen, lymph, lymph nodes, and other tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/3\">",
"     3",
"    </a>",
"    ], they are able to sample antigens derived from a wide range of distinct anatomical sites in search for a complementary peptide MHC complex. Following engagement of the appropriate complementary complex, a subpopulation of effector cells is activated and redirected to circulate between the blood and peripheral tissues. This permits effector T cells to reach sites of infection.",
"   </p>",
"   <p>",
"    Activated T cells also migrate toward the periphery of the T cell rich areas to facilitate contact with the B cell-rich areas. This permits interactions with antigen-specific B cells, thereby providing T cell help for antibody production. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Overview of CD4+ T cell activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In summary, the following sequence of events takes place during activation of CD4+ T cells:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dendritic cells capture and process antigen from peripheral sites. They then migrate into lymph nodes and develop into mature antigen presenting cells.",
"     </li>",
"     <li>",
"      Naive T cells \"scan\" dendritic cells with their TCR, looking for complementary",
"      <span class=\"nowrap\">",
"       MHC/peptide",
"      </span>",
"      complexes.",
"     </li>",
"     <li>",
"      Antigen recognition triggers a complex cascade of intercellular membrane glycoprotein contacts, and intracellular biochemical signals.",
"     </li>",
"     <li>",
"      The T cell-APC (or other cell) interaction is modulated by alterations in the expression of surface molecules and cytokine secretion by both cells.",
"     </li>",
"     <li>",
"      Specific characteristics of the cytokine milieu and the combination of signals results in either activation or tolerization of the T cell; it also determines the effector phenotype of an activated cell.",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       activated/effector",
"      </span>",
"      T cell may then migrate into peripheral tissues, or undergo further interactions with other cells (eg, B cells) within lymphoid tissues.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     T cell activation via the two signal model",
"    </span>",
"    &nbsp;&mdash;&nbsp;The paradigm for T cell activation is the so-called \"two signal\" mode (",
"    <a class=\"graphic graphic_figure graphicRef72231 \" href=\"UTD.htm?16/15/16625\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signal 1 derives from contact of TCR-CD3 with a MHC-peptide complex.",
"      <br/>",
"      <br/>",
"      It is possible, particularly where agonist (foreign)",
"      <span class=\"nowrap\">",
"       peptide/MHC",
"      </span>",
"      complexes occur at very low density on the APC surface, that endogenous (self)",
"      <span class=\"nowrap\">",
"       peptide/MHC",
"      </span>",
"      complexes also participate in the initiation of the immunological synapse [",
"      <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Signal 2 derives from costimulatory pathways (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=see_link\">",
"       \"Transplantation immunobiology\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Binding of TCR-CD3",
"    <strong>",
"     without",
"    </strong>",
"    engaging any costimulating molecules leads to a state of anergy (unresponsiveness or refractoriness to activation) and possibly even to deletion by apoptosis (death) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/5\">",
"     5",
"    </a>",
"    ]. This may be an important mechanism in T cell tolerance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5735?source=see_link\">",
"     \"Apoptosis and autoimmune disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies of gene expression profiles have shown that anergic cells express transcripts of cytokines that are characteristic of effector T cells, although they do not produce the cytokines upon TCR engagement due to a proximal signaling block [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/5\">",
"     5",
"    </a>",
"    ]. Anergic cells do still have the potential to be converted into effector cells, although extreme stimuli may be required (eg, immunization after transfer into another host).",
"   </p>",
"   <p>",
"    The manner in which costimulation converts anergy to activation is unknown. The interaction between CD28 expressed on T cells and CD80 and CD86 (B7-1 and B7-2) expressed on APCs is a very potent costimulatory system [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/5\">",
"     5",
"    </a>",
"    ]. A T cell expresses CD154 (CD40 ligand, CD40L) following activation via the TCR. CD40L binds to CD40 expressed on the APC surface and induces expression of CD80 and CD86 by the APC. Binding of these to CD28 on a resting T cell will not activate the cell, but once a T cell has been \"primed\" by antigen exposure, ligation of CD28 can trigger production of interleukin-2 (IL-2) and cellular proliferation. The simultaneous production of the cytokine IL-2, and a component of its high-affinity receptor (IL-2R alpha or CD25), initiates a positive feedback loop that is important for T cell proliferation.",
"   </p>",
"   <p>",
"    Inducible T cell costimulator (ICOS) is a CD28 homologue that is inducibly expressed on activated T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/5\">",
"     5",
"    </a>",
"    ]. Interaction with ICOS ligand (ICOS-L, a B7 homologue) may augment T cell activation. However, ICOS also appears to have other roles in modulating IL-10 production by Tregs and inhibiting development of Th17 cells. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Treg'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Th17'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A wide variety of additional signaling molecules expressed on T cells and APCs influence the activation or suppression and differentiation of T cells into",
"    <span class=\"nowrap\">",
"     effector/memory",
"    </span>",
"    or regulatory cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Intracellular events",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the cell surface molecules listed in the table may play a role in T cell activation (",
"    <a class=\"graphic graphic_table graphicRef72603 \" href=\"UTD.htm?12/6/12396\">",
"     table 1",
"    </a>",
"    ). During intercellular contact, many of these molecules interact with cytoskeletal elements, and are organized into specific regions within the zone of contact. This has been named the \"immunological synapse\" (",
"    <a class=\"graphic graphic_figure graphicRef69555 \" href=\"UTD.htm?17/63/18421\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A tremendously complex cascade of events within the cytoplasm ensues upon receptor and costimulator ligation (",
"    <a class=\"graphic graphic_figure graphicRef79731 \" href=\"UTD.htm?35/48/36611\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/7\">",
"     7",
"    </a>",
"    ]. T cell receptor signaling is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/26/25001?source=see_link\">",
"     \"T cell receptor signaling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cytokine secretion profiles of activated T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activated T cells are subdivided into distinct functional categories depending upon the profile of secreted cytokines (",
"    <a class=\"graphic graphic_table graphicRef63847 \" href=\"UTD.htm?16/19/16699\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/8\">",
"     8",
"    </a>",
"    ]. The conditions under which a T cell is stimulated have great influence on the functional phenotype of the activated cell. The route by which antigens enter the body (eg, skin, gut, etc), the form of the antigen (inert molecules, living microorganisms), and the amount of antigen are all important factors. At the cellular level during T cell stimulation, the degree of T cell receptor occupancy, the activity of various costimulatory pathways, and the presence of certain cytokines all influence the phenotype of activated cells. As examples, IL-12 and IFN-gamma are the cytokines that drive Th1 cell development, while IL-4 is critical for determining Th2 development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=see_link\">",
"     \"T helper subsets: Differentiation and role in disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Four major subsets have been distinguished for CD4+ T cells: Th1, Th2, Th17, and Treg (",
"    <a class=\"graphic graphic_table graphicRef63847 \" href=\"UTD.htm?16/19/16699\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/8\">",
"     8",
"    </a>",
"    ]. Additional patterns of cytokine production have been described (eg, Th9 and Th22 cells producing IL-9 and IL-22, respectively). However, it is not clear that these and others represent distinct functional subtypes.",
"   </p>",
"   <p>",
"    The Th1 and Th2 patterns have been most extensively studied. These patterns are to some degree mutually exclusive, as one pattern often clearly predominates in the context of a particular immune response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Th1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Th1 responses promote production of opsonizing antibodies (eg, IgG1) and induction of cellular cytotoxicity and macrophage activation. Th1 responses are prominent in the defense against pathogens that replicate intracellularly, and appear to be more common in pathological autoimmune responses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Th2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Th2 responses promote production of IgE and IgG4, and stimulate eosinophil development. Th2 responses are characteristic of helminth infection and are also involved in the pathogenesis of atopic diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Th17",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under the influence of IL-6 and TGF-beta, T cells develop into IL-17 secreting Th17 cells. These cells appear to have a role in driving chronic inflammatory responses in chronic infection, allergy, and autoimmunity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Treg",
"    </span>",
"    &nbsp;&mdash;&nbsp;These cells are central to the establishment and maintenance of tolerance. They play a principal role in negative regulation of the immune response. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Suppression'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Memory T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;When naive T cells are activated, some become short-lived effector T cells, while others become long-lived memory T cells. In comparison to naive T cells, memory T cells are activated more easily and rapidly in secondary immune responses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/9\">",
"     9",
"    </a>",
"    ]. This results from alterations in surface molecules, as well as intracellular differences in signaling (",
"    <a class=\"graphic graphic_table graphicRef82133 \" href=\"UTD.htm?11/22/11628\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/9\">",
"     9",
"    </a>",
"    ]. There may be many distinct functional classes of memory T cells having different migration patterns within tissues, different properties with respect to ease of stimulation and kinetics, and requirements for maintenance. However, these issues require much additional study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CELLULAR REGULATION OF IMMUNE RESPONSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune effector mechanisms are powerful processes of cell and tissue destruction. It is of clear benefit to maintain close control over immune system activation, so that we are not unnecessarily exposed to its degradative potential. T cells are critical in the regulation of both humoral (antibody) and cellular effector mechanisms. Antibody responses to the vast majority of protein and glycoprotein antigens require T cell help. Regulatory T cells also control specific cellular cytotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. T cell regulation is mediated by cellular contacts and soluble factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Positive regulation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Cognate T helper cell-B cell interaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed separately, effective antibody production against T-dependent antigens (most proteins and glycoproteins) requires cellular contact between B cells and T helper cells, as well as cytokine production by T cells. Naive T cells may be activated by APCs; they subsequently become effectors capable of activating antigen specific B cells that display the appropriate combination of MHC+peptide. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Activation of APCs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The T cell-APC interaction also results in an activated \"effector\" APC; this cell is then capable of elaborating higher concentrations of cytokines, increased phagocytosis and intracellular killing, as well as the capacity to activate cytotoxic T cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Negative regulation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Autoregulation via CTLA-4",
"    </span>",
"    &nbsp;&mdash;&nbsp;After activation, T cells reduce expression of CD28 and increase expression of cytotoxic T lymphocyte antigen 4 (CTLA-4), which has higher affinity for the ligands CD80 and CD86 (B7-1 and B7-2). This leads to loss of costimulation through CD28, resulting in cessation of proliferation and cytokine production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Inhibition via PD-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Programmed cell death-1 (PD-1) is an inhibitory homologue of CD28 that is expressed late after T cell activation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/5\">",
"     5",
"    </a>",
"    ]. PD-1 interacts with the inhibitory B7 homologues programmed death ligands 1 and 2 (PD-L1 and PD-L2). Ligation of PD-1 leads to inhibition of cytokine secretion and other effector functions of T cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Activation-induced cell death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following activation, T cells expand clonally, yielding large numbers of cytokine-producing cells; these activate potent inflammatory responses to combat infection. Unchecked T cell activation could lead to malignant proliferation or autoimmune disease. One fundamental mechanism of negative regulation of T cells is therefore activation-induced cell death (AICD) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/12\">",
"     12",
"    </a>",
"    ]. The same signals that lead to activation also set in motion a program of cell death (apoptosis) that may eventually kill the cell.",
"   </p>",
"   <p>",
"    Two important receptors promoting death of activated T cells are Fas (CD95, which binds Fas ligand or FasL) and TNF receptor 2 (TNFR2 or CD120b, which binds TNF-alpha). The interactions between these ligand pairs may occur on the same cell or between different cells. That is, the mechanism may be one of \"suicide\" or \"homicide.\" (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5735?source=see_link\">",
"     \"Apoptosis and autoimmune disease\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most T cells die within the thymus, either because they do not interact effectively with self-MHC molecules, or they display reactivity against self components. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .) However, this process is not perfect, and some self-reactive mature T cells exit the thymus and reach the periphery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/13\">",
"     13",
"    </a>",
"    ]. These cells must be inactivated (ie, made anergic) in order to prevent autoimmune disease. In addition, there must be a process to extinguish a protective immune response when it is no longer necessary. Mechanisms of immune suppression or regulation serve both of these functions.",
"   </p>",
"   <p>",
"    Regulatory T cells (Tregs) are stimulated in an antigen-specific manner through the TCR, but they may exert their suppressive effect specifically or non-specifically (\"bystander suppression\"). Tregs suppress autoimmunity and downregulate responses when they are no longer needed. However, they may contribute to disease through inappropriate downregulation of protective immune responses. As an example, elevated numbers of Tregs are found in solid tumors and in the draining lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/11\">",
"     11",
"    </a>",
"    ]. They are also found in higher numbers in the peripheral blood of individuals with hematologic malignancies or solid tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=see_link\">",
"     \"T helper subsets: Differentiation and role in disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Th3 subset of T cells is also a regulatory or suppressive population. They may contribute to the induction of peripheral Tregs by their production of TGF-beta [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another potentially regulatory or suppressive subset of T cells is called Tr1 cells. These cells produce IL-10 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/11\">",
"     11",
"    </a>",
"    ]. Both Tr1 and Th3 cells are prominent in intestinal mucosa and may have roles in the induction of tolerance to ingested antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     T cell cytotoxicity",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Activation of cytotoxic T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytotoxic T cells, the majority of which express the CD8 co-receptor for MHC class I, are also activated by professional APCs in lymphoid tissues, as are CD4-bearing cells. However, the APC must first be activated by contact with an antigen-specific CD4+ T cell before it is capable of inducing a naive CD8+ cell to become a full-fledged effector (cytotoxic) T cell [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/15\">",
"     15",
"    </a>",
"    ]. Direct CD4+ T cell help may also be required for primary CD8+ T cell responses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As mentioned above, virtually all cells process cytoplasmic molecules and present them on their surfaces in association with MHC class I. Thus, antigens derived from pathogens that replicate intracellularly are presented in this manner. Professional APCs may also present antigens internalized by phagocytosis via MHC class I [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/1\">",
"     1",
"    </a>",
"    ]. The degree to which MHC molecules bearing antigen cluster on the cell surface appears to affect the sensitivity of T cell recognition [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After acquiring effector function in lymphoid tissues, cytotoxic cells circulate in the periphery, \"searching\" for infected cells to kill. The first step in lysis is membrane contact between the cytotoxic and target cells. This contact is mediated by the",
"    <span class=\"nowrap\">",
"     TCR/CD8-MHC",
"    </span>",
"    class I interaction, as well as by several T",
"    <span class=\"nowrap\">",
"     cell/target",
"    </span>",
"    cell adhesion molecule interactions (eg, CD2 with CD58,",
"    <span class=\"nowrap\">",
"     CD11a/CD18",
"    </span>",
"    with CD54) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cytotoxicity occurs via two principal mechanisms: granule exocytosis and expression of the Fas ligand. CTL granules contain a variety of substances that enter the target cell and initiate apoptosis (programmed cell death). Granule contents enter the target cell through pores in the membrane created by the protein perforin, which has homology with complement factor C9. The molecules that initiate the cytotoxic process within the target cell are a family of at least 11 serine proteases called granzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/17\">",
"     17",
"    </a>",
"    ]. Although much of the biochemistry of granzymes is still unclear, some of their substrates may be precursor forms of caspases, a group of cytoplasmic enzymes that can trigger apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The other principal means of cell killing involves expression of the Fas ligand (FasL) on the surface of the effector CTL. If the target cell expresses the Fas molecule (CD95), ligation by FasL on the CTL will initiate a program of apoptosis in the target cell [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/17\">",
"     17",
"    </a>",
"    ]. It is unknown precisely under what circumstances a CTL will use one mechanism or the other. Of course, FasL expression is not relevant for target cells that do not express Fas.",
"   </p>",
"   <p>",
"    In addition to these cytotoxic mechanisms, CTLs also secrete a variety of cytokines, such as IFN-gamma and TNF that may directly damage target cells, or inhibit microbial replication. They also recruit and modulate additional inflammatory effector cells, such as macrophages. Although many experiments show the importance of these cytokines for resistance to a variety of microbes, it is not always clear that CTLs are the source in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A single CTL may \"recycle\" and lyse tens of target cells without itself suffering damage. It is unclear how CTLs are protected from the destructive potential of the molecules they discharge. CTLs are not themselves immune to lysis, since they may themselves be the targets of other cytotoxic cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Gamma-delta T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cells expressing the gamma-delta (TCR1) form of the TCR are a distinct functional class whose physiologic role is not yet understood. In normal individuals, about 1 to 5 percent of circulating T cells are TCR1+, the great majority of these cells are \"double-negative\" (DN or CD4-CD8-) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/18\">",
"     18",
"    </a>",
"    ]. As in blood, in secondary lymphoid tissues, the",
"    <span class=\"nowrap\">",
"     TCR1/TCR2",
"    </span>",
"    ratio is about",
"    <span class=\"nowrap\">",
"     1/50.",
"    </span>",
"    However, in other locations, such as gut epithelium, the ratio is",
"    <span class=\"nowrap\">",
"     1/5.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gamma-delta T cells have the capacity to interact with a variety of low molecular weight alkyl phosphates [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/18\">",
"     18",
"    </a>",
"    ]. Many such compounds may be found in mycobacterial cytoplasm. Alkylamines also stimulate gamma-delta T cells. The restricting elements for gamma-delta T cell antigen recognition are generally not classical MHC antigens, but non-classical MHC class I-like molecules, such as CD1, Qa, TL, or the MHC class I related genes MIC-A and B [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although gamma-delta cells may be stimulated by dendritic cells and other professional APCs, their ability to interact with non-classical MHC class I molecules may permit them to respond to antigens in situ when presented by other types of cells, such as intestinal enterocytes. The requirements for costimulation for gamma-delta cell activation are not yet clear. Some gamma-delta cells express CD28, but other mechanisms may operate in CD28- populations.",
"   </p>",
"   <p>",
"    TCR1+ T cells are expanded in a variety of infections, such as tuberculosis, leprosy, malaria, toxoplasmosis, EBV, CMV, HIV, and Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/18\">",
"     18",
"    </a>",
"    ]. In some murine models, this activity cannot be completely compensated by TCR2+ cells. This has not been clearly shown for humans. TCR1+ T cells are speculated to have some role in modulating or limiting inflammation initiated by TCR2+ T cells. Gamma-delta T cells do not appear to contribute to the memory T cell pool.",
"   </p>",
"   <p>",
"    Gamma-delta T cells having phenotypes similar to Th1, Th2, and cytotoxic and regulatory T cells have all been described [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6056/abstract/18\">",
"     18",
"    </a>",
"    ]. In some cases, these cells are CD4 or CD8 positive, indicating that they are not generally representative of TCR1+ cells. On the other hand, some are the more common DN type. Some have speculated that TCR1+ T cells are a more primitive form of cellular immunity, and that they represent a \"first line of defense\" during infection. Clearly, much remains to be learned regarding the physiological role(s) of gamma-delta T cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T cells are the effectors of antigen-specific cell-mediated immunity (CMI). CMI is important in the elimination of cells infected with pathogens that replicate intracellularly (eg, viruses, mycobacteria, and some bacteria) and cells exhibiting aberrant differentiation (eg, neoplasms). CMI also destroys allogeneic cells (graft rejection). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      T cell responses are initiated by antigen presenting cells, primarily dendritic cells. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Antigen presenting cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      T cell activation is thought to occur via a two-signal model. Signal 1 derives from contact of the T cell receptor-CD3 complex with a MHC-peptide complex. Signal 2 derives from costimulatory pathways. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'T cell activation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      T cells are critical in the regulation of both humoral (antibody) and cellular effector mechanisms. Antibody responses to the vast majority of protein and glycoprotein antigens require T cell help. Regulatory T cells also control specific cellular cytotoxicity. T cell regulation is mediated by cellular contacts and soluble factors. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Cellular regulation of immune responses'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6056/abstract/1\">",
"      Heath WR, Carbone FR. Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat Immunol 2009; 10:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6056/abstract/2\">",
"      Jenkins MK, Khoruts A, Ingulli E, et al. In vivo activation of antigen-specific CD4 T cells. Annu Rev Immunol 2001; 19:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6056/abstract/3\">",
"      Ley K, Kansas GS. Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation. Nat Rev Immunol 2004; 4:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6056/abstract/4\">",
"      Krogsgaard M, Li QJ, Sumen C, et al. Agonist/endogenous peptide-MHC heterodimers drive T cell activation and sensitivity. Nature 2005; 434:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6056/abstract/5\">",
"      Sharpe AH. Mechanisms of costimulation. Immunol Rev 2009; 229:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6056/abstract/6\">",
"      Kummerow C, Junker C, Kruse K, et al. The immunological synapse controls local and global calcium signals in T lymphocytes. Immunol Rev 2009; 231:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6056/abstract/7\">",
"      Salmond RJ, Filby A, Qureshi I, et al. T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance. Immunol Rev 2009; 228:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6056/abstract/8\">",
"      Veldhoen M. The role of T helper subsets in autoimmunity and allergy. Curr Opin Immunol 2009; 21:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6056/abstract/9\">",
"      Jameson SC, Masopust D. Diversity in T cell memory: an embarrassment of riches. Immunity 2009; 31:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6056/abstract/10\">",
"      Beyer M, Schultze JL. Regulatory T cells: major players in the tumor microenvironment. Curr Pharm Des 2009; 15:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6056/abstract/11\">",
"      Bour-Jordan H, Bluestone JA. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev 2009; 229:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6056/abstract/12\">",
"      Zhang J, Xu X, Liu Y. Activation-induced cell death in T cells and autoimmunity. Cell Mol Immunol 2004; 1:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6056/abstract/13\">",
"      Parish IA, Heath WR. Too dangerous to ignore: self-tolerance and the control of ignorant autoreactive T cells. Immunol Cell Biol 2008; 86:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6056/abstract/14\">",
"      Safadi R, Alvarez CE, Ohta M, et al. Enhanced oral tolerance in transgenic mice with hepatocyte secretion of IL-10. J Immunol 2005; 175:3577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6056/abstract/15\">",
"      Zhang S, Zhang H, Zhao J. The role of CD4 T cell help for CD8 CTL activation. Biochem Biophys Res Commun 2009; 384:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6056/abstract/16\">",
"      Fooksman DR, Gr&ouml;nvall GK, Tang Q, Edidin M. Clustering class I MHC modulates sensitivity of T cell recognition. J Immunol 2006; 176:6673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6056/abstract/17\">",
"      Henkart PA, Catalfamo M. CD8+ effector cells. Adv Immunol 2004; 83:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6056/abstract/18\">",
"      Hayday AC. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000; 18:975.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3980 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E570A510C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_58_6056=[""].join("\n");
var outline_f5_58_6056=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTIGEN PRESENTING CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism of presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      T CELL ACTIVATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Structure of the T cell receptor CD3 complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      T cell accessory molecules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      T cell interactions and movements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Overview of CD4+ T cell activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      T cell activation via the two signal model",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Intracellular events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cytokine secretion profiles of activated T cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Th1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Th2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Th17",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Treg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Memory T cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CELLULAR REGULATION OF IMMUNE RESPONSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Positive regulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Cognate T helper cell-B cell interaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Activation of APCs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Negative regulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Autoregulation via CTLA-4",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Inhibition via PD-1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Activation-induced cell death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Suppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      T cell cytotoxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Activation of cytotoxic T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Gamma-delta T cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3980\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3980|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/63/18421\" title=\"figure 1\">",
"      Immunologic synapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/15/16625\" title=\"figure 2\">",
"      Two signal model for T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/48/36611\" title=\"figure 3\">",
"      Major pathways of T cell activation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3980|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/6/12396\" title=\"table 1\">",
"      T cell surface protein function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/19/16699\" title=\"table 2\">",
"      T cell cytokine profiles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/22/11628\" title=\"table 3\">",
"      Diff naive and memory T cells",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25432?source=related_link\">",
"      Antigen presenting cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5735?source=related_link\">",
"      Apoptosis and autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=related_link\">",
"      Major histocompatibility complex (MHC) structure and function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37733?source=related_link\">",
"      T cell receptor genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/26/25001?source=related_link\">",
"      T cell receptor signaling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=related_link\">",
"      T helper subsets: Differentiation and role in disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=related_link\">",
"      The humoral immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=related_link\">",
"      Toll-like receptors: Roles in disease and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/27/10682?source=related_link\">",
"      Transplantation immunobiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_58_6057="Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases";
var content_f5_58_6057=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/58/6057/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/58/6057/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/58/6057/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/58/6057/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/58/6057/contributors\">",
"     Jerome B Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/58/6057/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/58/6057/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/58/6057/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain metastases are the most common intracranial tumors in adults, accounting for significantly more than one-half of brain tumors. In patients with systemic malignancies, brain metastases occur in 10 to 30 percent of adults and 6 to 10 percent of children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of brain metastases may be increasing, due to both improved detection of small metastases by magnetic resonance imaging (MRI) and better control of extracerebral disease resulting from improved systemic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/4-10\">",
"     4-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology, clinical manifestations, and diagnosis of brain metastases will be reviewed here, along with an overview of the approach to treatment. Specific treatment approaches to good and poor risk patients, as well as the use of systemic therapy, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link\">",
"     \"Treatment of brain metastases in favorable prognosis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36486?source=see_link\">",
"     \"Treatment of brain metastases in poor prognosis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/13/217?source=see_link\">",
"     \"Systemic therapy for brain metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRIMARY TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, the most common primary tumors responsible for brain metastases are carcinomas, and include lung, breast, kidney, and colorectal cancers, and melanoma. In contrast, carcinomas of the prostate, esophagus, and oropharynx and non-melanoma skin cancers rarely metastasize to the brain. In children, the most common sources of brain metastases are sarcomas, neuroblastoma, and germ cell tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/3,9,10\">",
"     3,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For all types of cancer, brain metastases diagnosed during life are relatively uncommon. This was illustrated in two large series, one from the Metropolitan Detroit Cancer Surveillance System and the other from a Dutch series [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In both studies, the cumulative incidence of brain metastases detected was similar:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lung &mdash; 16 to 20 percent",
"     </li>",
"     <li>",
"      Melanoma &mdash; 7 percent",
"     </li>",
"     <li>",
"      Renal cell cancer &mdash; 7 to 10 percent",
"     </li>",
"     <li>",
"      Breast cancer &mdash; 5 percent",
"     </li>",
"     <li>",
"      Colorectal cancer &mdash; 1 to 2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In autopsy series, the reported incidence of brain metastases varies widely, but is generally substantially higher than that diagnosed antemortem. This is illustrated by a review that found that brain metastases occur in as many as 64 percent of patients with lung cancer and 21 percent of those with breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Increasing incidence with advances in systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increases in the incidence of brain metastasis have been reported in several solid tumors, thought to be related, at least in part, to advances in the efficacy of systemic therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breast cancer &mdash; Among women with breast cancer, the incidence of brain metastasis may be increasing and is particularly high in those with lung metastases and highly-proliferative, hormone receptor-negative tumors that are positive for HER2 overexpression [",
"      <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/14-19\">",
"       14-19",
"      </a>",
"      ]. In one series, 15 of 50 patients (30 percent) presenting with lung metastases as the first site of relapse subsequently developed brain metastases during follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/14\">",
"       14",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Although tumor biology might also be at least partly responsible (ie, HER2-positive breast cancers have a higher propensity for metastases to sites such as lung and brain), it is also postulated that the lack of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      penetration into the central nervous system, owing to its high molecular weight, coupled with prolonged control of what was previously rapidly lethal systemic disease, leads to \"unmasking\" of brain metastases that would otherwise have remained clinically silent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19464?source=see_link\">",
"       \"Management of brain metastases in breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Colorectal cancer &mdash; The increasing incidence of brain metastases in patients with metastatic colorectal cancer has been attributed to the longer survival seen with newer systemic therapies [",
"      <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/9,20,21\">",
"       9,20,21",
"      </a>",
"      ]. Compared to the era when 5-fluorouracil was the primary agent for metastatic disease, median survival has increased markedly with the introduction of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      , and biologics (from 6 to 7 to approximately 24 months). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=see_link\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      However, the incidence of brain metastases in metastatic colorectal cancer is still low, 2.3 percent in one series [",
"      <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/22\">",
"       22",
"      </a>",
"      ]. Brain metastases are usually a late-stage phenomenon, and the vast majority of patients have metastases in other sites, particularly lung. Outcomes are poor, despite aggressive treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/23-25\">",
"       23-25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Non-small cell lung cancer &mdash; The increasing incidence of brain metastases in patients with non-small cell lung cancer is thought to be related, at least in part, to improved diagnosis of brain metastases with newer imaging modalities [",
"      <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Imaging studies'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39335?source=see_link\">",
"       \"Management of vasogenic edema in patients with primary and metastatic brain tumors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18697?source=see_link\">",
"       \"Seizures in patients with primary and metastatic brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common mechanism of metastasis to the brain is by hematogenous spread [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/21\">",
"     21",
"    </a>",
"    ]. Metastases are usually located directly at the junction of the gray matter and white matter where blood vessels decrease in diameter and act as a trap for clumps of tumor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/27\">",
"     27",
"    </a>",
"    ]. Brain metastases also tend to be more common at the terminal \"watershed areas\" of arterial circulation. The distribution of metastases roughly follows the relative weight and blood flow in each area [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cerebral hemispheres &mdash; approximately 80 percent",
"     </li>",
"     <li>",
"      Cerebellum &mdash; 15 percent",
"     </li>",
"     <li>",
"      Brainstem &mdash; 5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Different primary tumors may have a predilection for metastasis to different areas within the brain. For example, pelvic (prostatic and uterine), gastrointestinal, and breast tumors more commonly metastasize to the posterior fossa [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], while metastases of small cell carcinoma of the lung are equally distributed in all regions of the brain. The reasons for these differences are unclear but may be due to cell surface properties of the metastatic cells and the endothelium within the central nervous system (CNS) vasculature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain metastases have highly variable clinical features and should be suspected in any cancer patient who develops neurologic symptoms or behavioral abnormalities. However, multiple other causes can also be responsible. In an analysis of over 800 cancer patients evaluated for neurologic symptoms, only 16 percent had brain metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the majority of patients, a gradually expanding tumor mass and its associated edema cause symptoms. Less commonly, intratumoral hemorrhage, obstructive hydrocephalus, or embolization by tumor cells result in symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headaches occur in approximately 40 to 50 percent of patients with brain metastases. The frequency is higher when multiple lesions are present or a metastasis is located in the posterior fossa. Although the classic early morning headache is uncommon, it is highly suggestive when present.",
"   </p>",
"   <p>",
"    These general features were illustrated in a review of 111 consecutive patients with primary or metastatic brain tumors identified by CT or MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/30\">",
"     30",
"    </a>",
"    ]. Headache was present in 48 percent and equally affected those with primary and metastatic tumors. The headaches were similar to tension type in 77 percent, migraine in 9 percent, and other types in 14 percent. The typical headache was bifrontal but worse ipsilaterally; it was the worst symptom in about one-half of patients. In contrast to tension type headaches, brain tumor headaches were worse with bending over in 32 percent, and nausea or vomiting was present in 40 percent. Worsening headache may also follow maneuvers that raise intrathoracic pressure, such as coughing, sneezing, or the Valsalva maneuver. The \"classic\" early morning brain tumor headache was uncommon.",
"   </p>",
"   <p>",
"    Features suggestive of a possible brain tumor in the patient complaining of headaches include nausea and vomiting, a change in prior headache pattern, an abnormal neurologic examination, and positional worsening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/43/41655?source=see_link\">",
"     \"Brain tumor headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Focal neurologic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal neurologic dysfunction is the presenting symptom of 20 to 40 percent of patients. Hemiparesis is the most common complaint but the manifestations depend upon the location of the metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cognitive dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive dysfunction, including memory problems and mood or personality changes, is the presenting problem in 30 to 35 percent of patients. However, metabolic encephalopathy is a much more common cause of cognitive dysfunction than metastatic disease in cancer patients who develop an altered mental status [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;New onset of seizures is the presenting symptom in 10 to 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. Seizures in patients with brain metastases are almost exclusively associated with supratentorial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another 5 to 10 percent present acutely due to stroke caused by hemorrhage into a metastasis, hypercoagulability, invasion or compression of an artery by tumor, or embolization of tumor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/7,35\">",
"     7,35",
"    </a>",
"    ]. Melanoma, choriocarcinoma, and thyroid and renal carcinoma have a particular propensity to bleed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain metastases must be distinguished from primary brain tumors, infectious processes, progressive multifocal leukoencephalopathy, demyelination, paraneoplastic phenomena, cerebral infarction or bleeding, and effects of treatment such as radiation necrosis.",
"   </p>",
"   <p>",
"    Imaging studies provide useful information but brain biopsy is necessary in some cases for a definitive diagnosis. Other important diagnostic issues include determining the number and location of metastases and the evaluation of the patient without a known primary tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrast-enhanced MRI is the preferred imaging study for the diagnosis of brain metastases (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56550 \" href=\"UTD.htm?32/58/33698\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. Contrast-enhanced MRI is more sensitive than either nonenhanced MRI or CT scanning in detecting lesions in patients suspected of having cerebral metastases and in differentiating metastases from other central nervous system (CNS) lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In one report of 23 patients, for example, contrast-enhanced MRI demonstrated more than 67 definite or typical parenchymal metastases compared to more than 40 with T2-weighted MRI and 37 with double-dose contrast-enhanced CT [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographic features that can help differentiate brain metastases from other CNS lesions include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of multiple lesions",
"     </li>",
"     <li>",
"      Localization at the junction of the grey and white matter",
"     </li>",
"     <li>",
"      Circumscribed margins",
"     </li>",
"     <li>",
"      Large amounts of vasogenic edema compared to the size of the lesion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Experimental techniques such as magnetization transfer (MT) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/40,41\">",
"     40,41",
"    </a>",
"    ] and triple dose gadolinium imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/42-45\">",
"     42-45",
"    </a>",
"    ] have further improved lesion detection with MRI. In one study of 52 patients, for example, MT imaging showed more metastases than gradient-echo T1-weighted images in 23 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/41\">",
"     41",
"    </a>",
"    ]. Newer modalities such as echo planar imaging, spectroscopy, PET, and SPECT, also may prove to be useful [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/38\">",
"     38",
"    </a>",
"    ]. They are mainly used to differentiate tumor from radiation necrosis rather than for the initial diagnosis of brain metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy should be performed when the diagnosis of brain metastases is in doubt. This is particularly important in patients with a single lesion. The importance of biopsy was demonstrated in a study in which the diagnosis of metastasis was changed by biopsy in 6 of 54 patients with a single lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/46\">",
"     46",
"    </a>",
"    ]. These six patients had primary brain tumors, infections, or inflammatory processes.",
"   </p>",
"   <p>",
"    Breast cancer patients with a single dural-based lesion pose a particular diagnostic dilemma, since the incidence of meningiomas is increased in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/47\">",
"     47",
"    </a>",
"    ]. Imaging studies are often inconclusive, and biopsy or surgical resection of the lesion may be required to establish the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25540?source=see_link&amp;anchor=H22#H22\">",
"     \"Meningioma: Clinical presentation and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Unknown primary tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;In about 80 percent of patients, brain metastases develop after the diagnosis of systemic cancer (metachronous presentation) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/1\">",
"     1",
"    </a>",
"    ]. In the remaining patients, brain metastases become evident either at the same time (synchronous presentation) or before the primary tumor is found (precocious presentation). In these situations, histopathology of the biopsy specimen, including immunohistochemistry, can often help identify the primary [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who present with biopsy-proven brain metastases without a known primary tumor, the lung should be the primary focus of the evaluation. Over 60 percent of such patients have a primary lung cancer or pulmonary metastases from a primary tumor located elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. Other relatively frequent sites include melanoma, colon cancer, and breast cancer, while the primary remains unknown in approximately 25 to 30 percent of cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14758?source=see_link\">",
"     \"Overview of the classification and management of cancers of unknown primary site\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The history and physical examination demonstrate the site of origin in one-quarter to one-third of patients. In the others, a chest radiograph should be the first imaging test obtained. If this is nondiagnostic, a chest CT scan should be performed since this significantly increases the likelihood of detecting a lung tumor. This was illustrated in a report of 31 patients who presented with brain metastases without a known primary and subsequently were determined to have primary lung cancer by CT scan; chest radiographs were positive in only 19 (59 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/49\">",
"     49",
"    </a>",
"    ]. These patients should also have a CT scan of the abdomen and pelvis and a bone scan to determine the extent of metastatic disease.",
"   </p>",
"   <p>",
"    Positron emission tomography (PET) may also be useful in these patients, either by identifying the primary tumor or by finding other sites of metastatic disease that can be biopsied more readily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Number of metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a single or limited number of small metastases should be differentiated from those with more extensive involvement since treatment may be different. Although earlier studies based upon CT scans suggested that as many as 50 percent of patients had a single metastasis, MRI suggests that the true frequency of single metastases is lower, accounting for only one-fourth to one-third of patients with cerebral metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/6,36,37\">",
"     6,36,37",
"    </a>",
"    ]. Metastases from breast, colon, and renal cell carcinoma are more often single, while lung cancer and malignant melanoma have a greater tendency to produce multiple metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OVERVIEW OF MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with brain metastases includes specific treatments directed against the brain metastases, the management or prevention of complications (eg, seizures, cerebral edema, prevention of deep venous thrombosis), and treatment of systemic malignancy if appropriate.",
"   </p>",
"   <p>",
"    One of the key elements in planning treatment is to assess the patient's overall prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Prognostic classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The median survival of patients who receive supportive care and are treated only with corticosteroids is approximately one to two months. The use of whole brain radiation therapy in large series increased the average survival to three to six months, and larger gains were seen in carefully selected subsets [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The key parameters that determine survival after the diagnosis of brain metastases are performance status, the extent of extracranial disease, and age, as well as the primary diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12085144\">",
"    <span class=\"h3\">",
"     Recursive partitioning analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recursive partitioning analysis (RPA) utilized all of these factors, except for primary diagnosis, to divide patients into three categories: good, intermediate, and poor-risk groups [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/53\">",
"     53",
"    </a>",
"    ]. The RPA classification system has been widely used since its original description. The RPA system was based upon an analysis of prognostic factors in 1200 patients from three Radiation Therapy Oncology Group (RTOG) brain metastases trials.",
"   </p>",
"   <p>",
"    The three prognostic classes were correlated with median survival (",
"    <a class=\"graphic graphic_table graphicRef77561 \" href=\"UTD.htm?7/63/8187\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class 1 &mdash; The best prognosis was seen in patients who had a Karnofsky performance score 70 or higher (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 2",
"      </a>",
"      ), were less than 65 years of age, and had a controlled primary tumor without extracranial metastases. Median survival was 7.1 months. These patients are considered to have a favorable prognosis.",
"     </li>",
"     <li>",
"      Class 3 &mdash; Patients with a Karnofsky performance score less than 70 constituted the worst prognostic subset and had a median survival of 2.3 months. This group is considered to have a poor prognosis.",
"     </li>",
"     <li>",
"      Class 2 &mdash; This intermediate prognosis group included those with a Karnofsky performance score 70 or higher, but with other unfavorable characteristics (eg, uncontrolled primary tumor, other extracranial metastases, age &gt;65 years). Median survival in this group was 4.2 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients in this intermediate prognosis group are treated as either favorable or poor prognosis, depending largely upon the likelihood of controlling systemic disease.",
"   </p>",
"   <p>",
"    These results were subsequently validated in another RTOG trial that included 445 patients with brain metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/54\">",
"     54",
"    </a>",
"    ]. The median survival was 6.2 months for class 1 patients and 3.8 months for those in class 2.",
"   </p>",
"   <p>",
"    In the original RTOG analysis, approximately 20, 65, and 15 percent of the patients were in classes 1, 2, and 3, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/8\">",
"     8",
"    </a>",
"    ]. Although the trials used for this analysis excluded patients with small cell lung cancer (SCLC), a subsequent analysis of 154 patients with brain metastases from SCLC has confirmed the validity of RPA in this population as well [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12085237\">",
"    <span class=\"h3\">",
"     Diagnosis-specific graded prognostic assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival results following treatment for brain metastases are highly heterogeneous and depend in part upon the primary tumor.",
"   </p>",
"   <p>",
"    This observation led to criteria for diagnosis-specific graded prognostic assessment (DS-GPA) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/56\">",
"     56",
"    </a>",
"    ]. The DS-GPA system is based upon an analysis of 3940 patients with newly diagnosed brain metastases treated between 1985 and 2007. Multivariate analysis of patients in this database led to the establishment of separate criteria for patients with lung cancer (both non-small cell and small cell), melanoma, renal cell carcinoma, breast cancer, and gastrointestinal cancer.",
"   </p>",
"   <p>",
"    Significant prognostic factors in this model included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lung cancer: Age, Karnofsky performance score, presence of extracranial metastases, and number of brain metastases.",
"     </li>",
"     <li>",
"      Melanoma: Karnofsky performance score and number of brain metastases.",
"     </li>",
"     <li>",
"      Renal cell carcinoma: Karnofsky performance score and number of brain metastases",
"     </li>",
"     <li>",
"      Breast cancer: Karnofsky performance score, subtype (based upon estrogen",
"      <span class=\"nowrap\">",
"       receptor/progesterone",
"      </span>",
"      receptor, HER2 status), and age.",
"     </li>",
"     <li>",
"      Gastrointestinal cancers: Karnofsky performance score.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For each of these disease categories, there was a statistically significant survival gradient with improvement in overall survival with a better DS-GPA score (",
"    <a class=\"graphic graphic_table graphicRef65322 \" href=\"UTD.htm?18/13/18654\">",
"     table 3",
"    </a>",
"    ). These criteria provide improved prognostic information that may be useful patient management as well as clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Antitumor treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with brain metastases is strongly influenced by the patient's overall prognosis, and can include specific therapy directed against brain metastases and systemic therapy, as well as symptomatic treatment or prevention of complications of brain metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Treatment of the brain metastases",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients being managed as having a favorable prognosis, treatment focuses on the eradication or control of the brain metastases. These approaches include surgical resection and various forms of radiation therapy (eg, whole brain, stereotactic radiosurgery). These antitumor treatment approaches in patients with a favorable prognosis are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link\">",
"       \"Treatment of brain metastases in favorable prognosis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In those patients considered to have a poor prognosis, treatment focuses on control of symptoms caused by the brain metastases, as well as maintenance of neurologic function to as great an extent as possible. The management of patients with brain metastases and a poor prognosis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36486?source=see_link\">",
"       \"Treatment of brain metastases in poor prognosis patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with brain metastases from solid tumors do not present with isolated intracranial disease. These patients may also require systemic therapy as part of their overall management, as well as treatment targeting the brain metastases.",
"   </p>",
"   <p>",
"    Although systemic therapy may have some activity, this is generally not adequate treatment for brain metastases, even for chemosensitive malignancies. The rationale and limitations of systemic therapy in the treatment of brain metastases, as well as its potential application to patients with specific tumor types, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/13/217?source=see_link\">",
"     \"Systemic therapy for brain metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Symptom management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Key components of symptom management include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Control of peritumoral edema and increased intracranial pressure with corticosteroids. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39335?source=see_link\">",
"       \"Management of vasogenic edema in patients with primary and metastatic brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment and prevention of seizures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18697?source=see_link\">",
"       \"Seizures in patients with primary and metastatic brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Management and prevention of venous thromboembolic disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/39/30327?source=see_link\">",
"       \"Anticoagulant and antiplatelet therapy in patients with brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H876240\">",
"    <span class=\"h2\">",
"     Driving",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of asymptomatic or minimally symptomatic brain metastases has increased, possibly due to improvements in diagnostic techniques and systemic therapy. The appropriate recommendations regarding driving or operating hazardous equipment in individuals with brain metastases who have not experienced a seizure is unclear.",
"   </p>",
"   <p>",
"    In patients whose cognitive functions and detailed neurological examination are essentially normal, there is no medical contraindication to driving. However, for patients with any neurologic deficit, reflexes may be slower and judgment may not be entirely normal. A formal driving evaluation may be useful if there is any question of slow reflexes or impaired judgement.",
"   </p>",
"   <p>",
"    Driving by patients who have experienced a seizure is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32568?source=see_link\">",
"     \"Driving restrictions for patients with seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/48/9986?source=see_link\">",
"       \"Patient information: Brain cancer (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/12/19650?source=see_link\">",
"       \"Patient information: Brain metastases (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/42/36515?source=see_link\">",
"       \"Patient information: Primary low-grade glioma in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/52/8004?source=see_link\">",
"       \"Patient information: High-grade glioma in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/15/5362?source=see_link\">",
"       \"Patient information: Meningioma (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain metastases are the most common intracranial tumors in adults, occurring in about 10 percent of cancer patients at some point during their illness and accounting for significantly more than one-half of all brain tumors. Lung cancer, melanoma, renal cell carcinoma, and breast cancer are the most common primary tumors that metastasize to the brain.",
"   </p>",
"   <p>",
"    Metastases can cause a variety of symptoms, including headache, focal neurologic deficits, cognitive dysfunction, seizures, and stroke. The development of any neurologic symptom in a patient with cancer requires consideration of the diagnosis of metastasis, although other causes are responsible in the majority of instances [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6057/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contrast-enhanced MRI is the most reliable imaging procedure to make the diagnosis. In patients with a single intracranial lesion, biopsy may be required to make a definitive diagnosis (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical manifestations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Diagnosis'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Patient treatment depends upon the overall prognosis, and includes specific measures directed against metastases as well as the prevention and management of complications. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Prognostic classification'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H18\">",
"     'Antitumor treatment'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H21\">",
"     'Symptom management'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/1\">",
"      Posner JB. Management of brain metastases. Rev Neurol (Paris) 1992; 148:477.",
"     </a>",
"    </li>",
"    <li>",
"     Sawaya R, Bindal RK. Metastatic brain tumors. In: Brain Tumors, Kaye AH, Laws ER (Eds), Churchill Livingstone, Edinburgh 1995. p.923.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/3\">",
"      Graus F, Walker RW, Allen JC. Brain metastases in children. J Pediatr 1983; 103:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/4\">",
"      Wen PY, Loeffler JS. Management of brain metastases. Oncology (Williston Park) 1999; 13:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/5\">",
"      Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin N Am 1996; 7:337.",
"     </a>",
"    </li>",
"    <li>",
"     Loeffler JS, Patchell RA, Sawaya R. Metastatic brain cancer. In: Cancer: Principles and Practice of Oncology, Davita VT, Hellman S, Rosenberg SA (Eds), JP Lippincott, Philadelphia 1997. p.2523.",
"    </li>",
"    <li>",
"     Posner JB. Neurologic Complications of Cancer, FA Davis, Philadelphia 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/8\">",
"      Paterson AH, Agarwal M, Lees A, et al. Brain metastases in breast cancer patients receiving adjuvant chemotherapy. Cancer 1982; 49:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/9\">",
"      Sundermeyer ML, Meropol NJ, Rogatko A, et al. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 2005; 5:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/10\">",
"      Bouffet E, Doumi N, Thiesse P, et al. Brain metastases in children with solid tumors. Cancer 1997; 79:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/11\">",
"      Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004; 22:2865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/12\">",
"      Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002; 94:2698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/13\">",
"      Lassman AB, DeAngelis LM. Brain metastases. Neurol Clin 2003; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/14\">",
"      Slimane K, Andre F, Delaloge S, et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 2004; 15:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/15\">",
"      Crivellari D, Pagani O, Veronesi A, et al. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 2001; 12:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/16\">",
"      Miller KD, Weathers T, Haney LG, et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 2003; 14:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/17\">",
"      Tham YL, Sexton K, Kramer R, et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006; 107:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/18\">",
"      Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007; 13:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/19\">",
"      Gori S, Rimondini S, De Angelis V, et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 2007; 12:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/20\">",
"      Kruser TJ, Chao ST, Elson P, et al. Multidisciplinary management of colorectal brain metastases: a retrospective study. Cancer 2008; 113:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/21\">",
"      Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neurooncol 2005; 75:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/22\">",
"      Mongan JP, Fadul CE, Cole BF, et al. Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin Colorectal Cancer 2009; 8:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/23\">",
"      Nieder C, Pawinski A, Balteskard L. Colorectal cancer metastatic to the brain: time trends in presentation and outcome. Oncology 2009; 76:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/24\">",
"      Aprile G, Zanon E, Tuniz F, et al. Neurosurgical management and postoperative whole-brain radiotherapy for colorectal cancer patients with symptomatic brain metastases. J Cancer Res Clin Oncol 2009; 135:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/25\">",
"      Baek JY, Kang MH, Hong YS, et al. Characteristics and prognosis of patients with colorectal cancer-associated brain metastases in the era of modern systemic chemotherapy. J Neurooncol 2011; 104:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/26\">",
"      Mamon HJ, Yeap BY, J&auml;nne PA, et al. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol 2005; 23:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/27\">",
"      Delattre JY, Krol G, Thaler HT, Posner JB. Distribution of brain metastases. Arch Neurol 1988; 45:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/28\">",
"      Quattrocchi CC, Errante Y, Gaudino C, et al. Spatial brain distribution of intra-axial metastatic lesions in breast and lung cancer patients. J Neurooncol 2012; 110:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/29\">",
"      Clouston PD, DeAngelis LM, Posner JB. The spectrum of neurological disease in patients with systemic cancer. Ann Neurol 1992; 31:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/30\">",
"      Forsyth PA, Posner JB. Headaches in patients with brain tumors: a study of 111 patients. Neurology 1993; 43:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/31\">",
"      Coia LR, Aaronson N, Linggood R, et al. A report of the consensus workshop panel on the treatment of brain metastases. Int J Radiat Oncol Biol Phys 1992; 23:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/32\">",
"      Cohen N, Strauss G, Lew R, et al. Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? A retrospective analysis. J Clin Oncol 1988; 6:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/33\">",
"      Glantz MJ, Cole BF, Friedberg MH, et al. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 1996; 46:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/34\">",
"      Forsyth PA, Weaver S, Fulton D, et al. Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci 2003; 30:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/35\">",
"      Nutt SH, Patchell RA. Intracranial hemorrhage associated with primary and secondary tumors. Neurosurg Clin N Am 1992; 3:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/36\">",
"      Sze G, Milano E, Johnson C, Heier L. Detection of brain metastases: comparison of contrast-enhanced MR with unenhanced MR and enhanced CT. AJNR Am J Neuroradiol 1990; 11:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/37\">",
"      Davis PC, Hudgins PA, Peterman SB, Hoffman JC Jr. Diagnosis of cerebral metastases: double-dose delayed CT vs contrast-enhanced MR imaging. AJNR Am J Neuroradiol 1991; 12:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/38\">",
"      Schaefer PW, Budzik RF Jr, Gonzalez RG. Imaging of cerebral metastases. Neurosurg Clin N Am 1996; 7:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/39\">",
"      Muroff LR, Runge VM. The use of MR contrast in neoplastic disease of the brain. Top Magn Reson Imaging 1995; 7:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/40\">",
"      Elster AD, Mathews VP, King JC, Hamilton CA. Improved detection of gadolinium enhancement using magnetization transfer imaging. Neuroimaging Clin N Am 1994; 4:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/41\">",
"      Peretti-Viton P, Taieb D, Viton JM, et al. Contrast-enhanced magnetisation transfer MRI in metastatic lesions of the brain. Neuroradiology 1998; 40:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/42\">",
"      Akeson P, Larsson EM, Kristoffersen DT, et al. Brain metastases--comparison of gadodiamide injection-enhanced MR imaging at standard and high dose, contrast-enhanced CT and non-contrast-enhanced MR imaging. Acta Radiol 1995; 36:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/43\">",
"      Runge VM, Wells JW, Nelson KL, Linville PM. MR imaging detection of cerebral metastases with a single injection of high-dose gadoteridol. J Magn Reson Imaging 1994; 4:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/44\">",
"      Yuh WT, Fisher DJ, Runge VM, et al. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases. AJNR Am J Neuroradiol 1994; 15:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/45\">",
"      Sze G, Johnson C, Kawamura Y, et al. Comparison of single- and triple-dose contrast material in the MR screening of brain metastases. AJNR Am J Neuroradiol 1998; 19:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/46\">",
"      Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/47\">",
"      Schoenberg BS, Christine BW, Whisnant JP. Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer. Neurology 1975; 25:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/48\">",
"      Drlicek M, Bodenteich A, Urbanits S, Grisold W. Immunohistochemical panel of antibodies in the diagnosis of brain metastases of the unknown primary. Pathol Res Pract 2004; 200:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/49\">",
"      Latief KH, White CS, Protopapas Z, et al. Search for a primary lung neoplasm in patients with brain metastasis: is the chest radiograph sufficient? AJR Am J Roentgenol 1997; 168:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/50\">",
"      Merchut MP. Brain metastases from undiagnosed systemic neoplasms. Arch Intern Med 1989; 149:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/51\">",
"      van de Pol M, van Aalst VC, Wilmink JT, Twijnstra A. Brain metastases from an unknown primary tumour: which diagnostic procedures are indicated? J Neurol Neurosurg Psychiatry 1996; 61:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/52\">",
"      Mavrakis AN, Halpern EF, Barker FG 2nd, et al. Diagnostic evaluation of patients with a brain mass as the presenting manifestation of cancer. Neurology 2005; 65:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/53\">",
"      Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/54\">",
"      Gaspar LE, Scott C, Murray K, Curran W. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 2000; 47:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/55\">",
"      Videtic GM, Adelstein DJ, Mekhail TM, et al. Validation of the RTOG recursive partitioning analysis (RPA) classification for small-cell lung cancer-only brain metastases. Int J Radiat Oncol Biol Phys 2007; 67:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6057/abstract/56\">",
"      Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012; 30:419.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5217 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-B2407C6BAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_58_6057=[""].join("\n");
var outline_f5_58_6057=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRIMARY TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Increasing incidence with advances in systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Focal neurologic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cognitive dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Unknown primary tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Number of metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OVERVIEW OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Prognostic classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12085144\">",
"      - Recursive partitioning analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12085237\">",
"      - Diagnosis-specific graded prognostic assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Antitumor treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Treatment of the brain metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Symptom management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H876240\">",
"      Driving",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5217\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5217|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/58/33698\" title=\"diagnostic image 1\">",
"      Brain MRI CNS met melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5217|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/63/8187\" title=\"table 1\">",
"      Brain mets prognosis RTOG RPA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 2\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/13/18654\" title=\"table 3\">",
"      Graded prognostic assessment for brain metastases by diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/39/30327?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/43/41655?source=related_link\">",
"      Brain tumor headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32568?source=related_link\">",
"      Driving restrictions for patients with seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19464?source=related_link\">",
"      Management of brain metastases in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39335?source=related_link\">",
"      Management of vasogenic edema in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25540?source=related_link\">",
"      Meningioma: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14758?source=related_link\">",
"      Overview of the classification and management of cancers of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/48/9986?source=related_link\">",
"      Patient information: Brain cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/12/19650?source=related_link\">",
"      Patient information: Brain metastases (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/52/8004?source=related_link\">",
"      Patient information: High-grade glioma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/15/5362?source=related_link\">",
"      Patient information: Meningioma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/42/36515?source=related_link\">",
"      Patient information: Primary low-grade glioma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18697?source=related_link\">",
"      Seizures in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/13/217?source=related_link\">",
"      Systemic therapy for brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=related_link\">",
"      Treatment of brain metastases in favorable prognosis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36486?source=related_link\">",
"      Treatment of brain metastases in poor prognosis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_58_6058="Pruritus: Overview of management";
var content_f5_58_6058=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pruritus: Overview of management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/58/6058/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/58/6058/contributors\">",
"     Sara B Fazio, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/58/6058/contributors\">",
"     Gil Yosipovitch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/58/6058/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/58/6058/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/58/6058/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/58/6058/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/58/6058/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/58/6058/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H8354347\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pruritus is a common symptom that occurs in a wide variety of clinical settings, such as dermatologic disorders, neuropathic disorders, and systemic or psychiatric disease. In addition to physical effects (eg, skin injury, secondary infections, scarring, and loss of sleep), pruritus can contribute to emotional disturbances such as agitation and depression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/1\">",
"     1",
"    </a>",
"    ]. In severe cases, pruritus can be incapacitating.",
"   </p>",
"   <p>",
"    The inciting factor for pruritus and the extent and severity of symptoms influence the approach to treatment. While in some patients amelioration of pruritus is easily attained, treatment is extremely challenging in other individuals.",
"   </p>",
"   <p>",
"    A wide variety of therapies have been used for pruritus; however, data are limited on the efficacy of many treatment options (",
"    <a class=\"graphic graphic_table graphicRef50432 graphicRef63221 \" href=\"UTD.htm?1/33/1566\">",
"     table 1A-B",
"    </a>",
"    ). The therapies used for pruritus and the approach to the management of pruritus will be discussed here. Inciting factors for pruritus and the evaluation of patients with pruritus are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10090?source=see_link\">",
"     \"Pruritus: Etiology and patient evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354354\">",
"    <span class=\"h1\">",
"     THERAPEUTIC OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both nonpharmacologic and pharmacologic therapies may be beneficial in the treatment of pruritus. Topical therapies are commonly used for localized forms of pruritus; systemic agents are typically needed for patients with generalized symptoms. (See",
"    <a class=\"local\" href=\"#H8354368\">",
"     'Local pharmacologic therapies'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8354410\">",
"     'Systemic therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354361\">",
"    <span class=\"h2\">",
"     Nonpharmacologic interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The elimination of aggravating factors for pruritus is an important component of symptom management. Interventions that may be beneficial include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Skin moisturization &ndash;",
"      </strong>",
"      Dry skin can cause or exacerbate pruritus; thus, all patients with generalized symptoms should be educated on proper skin care. For example, gentle cleansers should be used during bathing and patients should apply emollients to the skin daily. (See",
"      <a class=\"local\" href=\"#H8354494\">",
"       'Xerosis (dry skin)'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Cool environment &ndash;",
"      </strong>",
"      Symptoms of pruritus may be exacerbated by exposure to heat. Light-weight clothing, air-conditioned environments, and the use of lukewarm (rather than hot) water during showers or baths may reduce symptoms. Lotions that provide a cooling sensation on the skin, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/11/33969?source=see_link\">",
"       calamine lotion",
"      </a>",
"      or lotions with up to a 4% concentration of menthol (eg, Sarna",
"      <sup>",
"       &reg;",
"      </sup>",
"      or Men-Phor&trade;) can provide additional relief.",
"     </li>",
"     <li>",
"      <strong>",
"       Avoidance of skin irritants &ndash;",
"      </strong>",
"      Direct contact with substances that may irritate the skin, such as wool clothing and cleansing products, should be avoided.",
"     </li>",
"     <li>",
"      <strong>",
"       Stress reduction &ndash;",
"      </strong>",
"      Stress and other psychogenic factors may induce or aggravate chronic itch [",
"      <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/2-5\">",
"       2-5",
"      </a>",
"      ], and stress reduction may help to reduce symptoms. In addition, psychological support and education on pruritus and behavioral interventions that minimize symptoms may help patients to cope [",
"      <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/1\">",
"       1",
"      </a>",
"      ]. Holistic approaches such as meditation, acupuncture, and yoga may be useful as adjunctive therapies [",
"      <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Physical interventions &ndash;",
"      </strong>",
"      Scratching may increase symptoms of pruritus, resulting in a perpetual itch-scratch cycle. Occlusion of localized areas of pruritus with Unna boots or other occlusive dressings (eg, DuoDerm&reg;) may help to break this cycle [",
"      <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/8\">",
"       8",
"      </a>",
"      ]. Keeping fingernails trimmed to a short length may also help to minimize skin damage induced from scratching.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354368\">",
"    <span class=\"h2\">",
"     Local pharmacologic therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical therapy is most useful for patients with localized forms of pruritus, such as limited dermatitis, lichen simplex chronicus, notalgia paresthetica, and brachioradial pruritus. A table that summarizes the options for local therapy is provided (",
"    <a class=\"graphic graphic_table graphicRef50432 \" href=\"UTD.htm?24/51/25404\">",
"     table 1A",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354375\">",
"    <span class=\"h3\">",
"     Topical and intralesional corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical corticosteroids are effective for the treatment of inflammatory skin disease, which often results in the concomitant relief of the associated pruritus. These agents are",
"    <strong>",
"     not",
"    </strong>",
"    indicated for pruritus without evidence of skin inflammation.",
"   </p>",
"   <p>",
"    Wet wraps, which involve the application of low to medium potency topical corticosteroids under moist dressings, are sometimes used in patients with atopic dermatitis or other inflammatory pruritic dermatoses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. For thick or nodular lesions, intralesional injection of corticosteroids may be more effective than topical agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Controlling pruritus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=see_link\">",
"     \"Intralesional injection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential adverse effects of topical corticosteroids include cutaneous atrophy and suppression of the hypothalamic-pituitary-axis. The side effects of topical corticosteroids are reviewed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354382\">",
"    <span class=\"h3\">",
"     Topical capsaicin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     Capsaicin",
"    </a>",
"    (8-methyl-N-vanillyl-6 nonenamide) is a substance derived from chili peppers that has been used for the treatment of chronic pain and pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/11\">",
"     11",
"    </a>",
"    ]. The mechanism of action for capsaicin involves its ability to activate transient release potential vanilloid-1 (TRPV1), an ion channel in cutaneous nerve fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Activation of TRPV1 stimulates neurons to release and eventually deplete certain neuropeptides, including substance P. Capsaicin also induces lasting desensitization of neurons to a variety of stimuli. In sum, these effects lead to the inhibition of neuronal transmission of pain and pruritus.",
"   </p>",
"   <p>",
"    Although a systematic review or randomized trials found insufficient evidence for definitive conclusions on the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    for pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/14\">",
"     14",
"    </a>",
"    ], multiple studies have documented the efficacy of this agent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. Neuropathic disorders such as notalgia paresthetica and brachioradial pruritus appear to be particularly responsive to this therapy. Prurigo nodularis, aquagenic pruritus, and pruritus associated with chronic renal disease are examples of other disorders that have been successfully treated with capsaicin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/11,20-22\">",
"     11,20-22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8354515\">",
"     'Peripheral neuropathic itch'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The acute stimulation of neuropeptide release that occurs early in the course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    therapy manifests as a transient, intense burning sensation that occurs immediately after application and lasts for up to 30 minutes. This adverse effect may contribute to poor compliance and premature treatment cessation, and patients should be informed that these symptoms usually resolve after two to three weeks of use. A topical anesthetic, such as eutectic mixture of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    2.5% and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/32/6660?source=see_link\">",
"     prilocaine",
"    </a>",
"    2.5% cream (EMLA) or a 5% lidocaine patch applied 30 to 60 minutes prior to treatment may minimize the burning sensation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354389\">",
"    <span class=\"h3\">",
"     Topical calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical calcineurin inhibitors are used for the treatment of multiple inflammatory skin diseases. The commercially available products include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    0.03% and 0.1% ointments and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    1% cream.",
"   </p>",
"   <p>",
"    Topical calcineurin inhibitors have been associated with reduced itch in patients with atopic dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/24\">",
"     24",
"    </a>",
"    ], as well as in patients with other disorders, such as prurigo nodularis, anogenital pruritus, psychogenic pruritus, lichen sclerosus, chronic hand dermatitis, and chronic graft-versus-host disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition to the suppression of cutaneous inflammation, phosphorylation of TRPV1 has been proposed as another mechanism through which topical calcineurin inhibitors reduce pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects of topical calcineurin inhibitors include a burning sensation after application, which may be a result of initial release of substance P, as has been described with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/26\">",
"     26",
"    </a>",
"    ]. Although concern has been raised over the possibility of an increased risk for malignancy with the use of these agents, the risk for malignancy appears to be low. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354396\">",
"    <span class=\"h3\">",
"     Topical anesthetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical anesthetics exhibit antipruritic effects.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/5/17491?source=see_link\">",
"     Pramoxine",
"    </a>",
"    1% cream, eutectic mixture of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    2.5% and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/32/6660?source=see_link\">",
"     prilocaine",
"    </a>",
"    2.5% cream (EMLA",
"    <sup>",
"     &reg;",
"    </sup>",
"    ), and an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14370?source=see_link\">",
"     ethyl chloride",
"    </a>",
"    spray have demonstrated antipruritic effects in experimental settings [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical studies also have supported the utility of topical anesthetics for pruritus. A four-week randomized trial in 28 patients with uremic pruritus found that the percent reduction in itch intensity was greater after application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/5/17491?source=see_link\">",
"     pramoxine",
"    </a>",
"    1% lotion twice daily to areas of pruritus than after application of a control lotion (61 versus 12 percent reduction) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/30\">",
"     30",
"    </a>",
"    ]. In addition, eutectic mixture of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    2.5% and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/32/6660?source=see_link\">",
"     prilocaine",
"    </a>",
"    2.5% was effective for post-burn pruritus in a pilot study of five children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/31\">",
"     31",
"    </a>",
"    ], and topical lidocaine in an acid mantle cream reduced pruritus in an early, uncontrolled study of 50 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/32\">",
"     32",
"    </a>",
"    ]. Patients with neuropathic itch due to notalgia paresthetica have also benefited from treatment with topical anesthetics [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8354515\">",
"     'Peripheral neuropathic itch'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/6/110?source=see_link\">",
"     Polidocanol",
"    </a>",
"    is a non-ionic surfactant primarily used for sclerotherapy that possesses both local anaesthetic properties and moisturizing effects. An open label study of 1611 patients with eczematous dermatitis or psoriasis found that a preparation with polidocanol and urea appeared to improve pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/34\">",
"     34",
"    </a>",
"    ]. Topical polidocanol is commercially available in Europe, Asia, and Australia, but not in the United States.",
"   </p>",
"   <p>",
"    Toxicity due to systemic absorption may occur with improper use of topical anesthetics. Methemoglobinemia is a potential consequence of EMLA use in young children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=see_link\">",
"     \"Topical anesthetics in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354403\">",
"    <span class=\"h3\">",
"     Topical antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several randomized trials support the use of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    for pruritus in the setting of skin disease, such as atopic dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/35\">",
"     35",
"    </a>",
"    ]. However, data are insufficient to draw conclusions on the efficacy of other topical antihistamines, including topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential adverse effects of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    include drowsiness, contact dermatitis, and stinging or burning at the site of application.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354410\">",
"    <span class=\"h2\">",
"     Systemic therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although topical agents are useful for the treatment of localized disease, systemic agents are typically employed for the treatment of generalized pruritus. Antihistamines and agents that act upon the central nervous system have been used for management. A table that summarizes the options for systemic therapy is provided (",
"    <a class=\"graphic graphic_table graphicRef63221 \" href=\"UTD.htm?5/8/5261\">",
"     table 1B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354417\">",
"    <span class=\"h3\">",
"     Antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral H1 antihistamines function through the blockage of H1 receptors on afferent C nerve fibers and may also inhibit the release of pruritic mediators from mast cells when administered at high doses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link\">",
"     \"New onset urticaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the relative safety, wide availability, and affordability of these agents, H1 antihistamines are often the first systemic therapies attempted in patients with widespread pruritus. However, with the exception of urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/37\">",
"     37",
"    </a>",
"    ] and mastocytosis, disorders in which histamine is known to play an important role, data on the efficacy of systemic antihistamines for pruritus are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/38\">",
"     38",
"    </a>",
"    ]. A systematic review of randomized trials found insufficient evidence to confirm or negate the utility of H1 antihistamines in patients with atopic dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the utility of antihistamines for most causes of pruritus is unclear, the soporific effects of first generation (sedating) H1 antihistamines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ) are often beneficial in patients who suffer from exacerbations of pruritus at night [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/38\">",
"     38",
"    </a>",
"    ]. Sedation during the day is generally unwanted and may be hazardous, particularly in elderly patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354424\">",
"    <span class=\"h3\">",
"     Opioid receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activation of &mu;-opioid receptors in the central nervous system may contribute to itch through suppression of the inhibitory effect of pain-transmitting neurons on pruriceptive neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/36,40\">",
"     36,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The &mu;-opioid receptor antagonists",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    , and nalmefene appear to be effective against some forms of pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/41\">",
"     41",
"    </a>",
"    ]. In randomized trials, these agents have been beneficial for the treatment of pruritus secondary to cholestasis, chronic urticaria, atopic dermatitis, and epidural",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    administration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In addition, cases in which opioid receptor antagonists were used successfully for the treatment of prurigo nodularis, mycosis fungoides, aquagenic pruritus, and other pruritic disorders have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/41\">",
"     41",
"    </a>",
"    ]. There are conflicting results from randomized trials of naltrexone in uremic pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6937?source=see_link\">",
"     \"Uremic pruritus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The widespread use of opioid receptor antagonists has been limited due to a high rate of initial adverse effects.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2516?source=see_link\">",
"     Methylnaltrexone",
"    </a>",
"    is a peripherally acting opioid receptor antagonist that may have benefit in the management of pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. However, further studies are necessary to determine the efficacy of this drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354431\">",
"    <span class=\"h3\">",
"     Opioid receptor agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activation of &kappa;-opioid receptors in the central nervous system may inhibit itch [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/40\">",
"     40",
"    </a>",
"    ]. The &kappa;-opioid receptor agonists",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9543?source=see_link\">",
"     butorphanol",
"    </a>",
"    and nalfurafine have been used for pruritic disorders. In a case series of five patients with intractable pruritus due to inflammatory skin disease or systemic disorders, intranasal butorphanol was associated with rapid and marked improvement. Most patients responded to a dose of 1 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/47\">",
"     47",
"    </a>",
"    ]. In addition, a Phase III placebo-controlled trial involving 337 patients with pruritus related to chronic kidney disease found that oral nalfurafine reduced itch [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354438\">",
"    <span class=\"h3\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective norepinephrine reuptake inhibitors (SNRIs) may have efficacy for pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/49\">",
"     49",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     Mirtazapine",
"    </a>",
"    , an SNRI with H1 antihistaminic properties, has been linked to improvement in pruritus in individual patients with malignant cholestasis, lymphoma, uremia, atopic dermatitis, or neurotic excoriations with concomitant lichen simplex chronicus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. In addition, in a randomized trial of 110 patients who were treated with intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , prophylactic mirtazapine was associated with a reduced incidence of pruritus after morphine therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism through which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    reduces pruritus is not definitively known. Mirtazapine acts as an antagonist at noradrenergic &alpha;",
"    <sub>",
"     2",
"    </sub>",
"    -receptors and 5-HT",
"    <sub>",
"     2",
"    </sub>",
"    and 5-HT",
"    <sub>",
"     3",
"    </sub>",
"    serotonin receptors, increasing central noradrenergic and 5-HT",
"    <sub>",
"     1",
"    </sub>",
"    serotonergic neurotransmission. The drug also antagonizes H1 receptors.",
"   </p>",
"   <p>",
"    The most common adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    include somnolence, hypercholesterolemia, constipation, xerostomia, and weight gain. In concert with its sedative effects, mirtazapine may be especially useful in patients with nocturnal pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Selective serotonin reuptake inhibitors (SSRIs) have also demonstrated efficacy in pruritus. In an open-label study in which 72 patients with severe, chronic pruritus were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    , 68 percent of patients had a mild, good, or very good response to treatment. The most favorable responses occurred in patients with atopic dermatitis, systemic lymphoma and solid carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/54\">",
"     54",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     Sertraline",
"    </a>",
"    , another SSRI, has demonstrated efficacy for pruritus associated with cholestatic liver disease in a small open label study and a retrospective case series [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to other antihistaminic agents, further studies are necessary to determine the antipruritic efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    , a tricyclic antidepressant with antihistaminic properties. (See",
"    <a class=\"local\" href=\"#H8354417\">",
"     'Antihistamines'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354445\">",
"    <span class=\"h3\">",
"     Anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticonvulsants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    are structural analogs of the neurotransmitter &gamma;-aminobutyric acid (GABA). The mechanism through which these agents improve pruritus is unknown. Gabapentin and pregabalin may be particularly useful in forms of neuropathic pruritus related to nerve entrapment disorders such as brachioradial pruritus and notalgia paresthetica (see",
"    <a class=\"local\" href=\"#H8354515\">",
"     'Peripheral neuropathic itch'",
"    </a>",
"    below). There have been case reports suggesting that gabapentin also may be beneficial in patients with idiopathic pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354459\">",
"    <span class=\"h3\">",
"     Aprepitant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvement in refractory pruritus has been reported in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    , a neurokinin receptor 1 antagonist [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/58-64\">",
"     58-64",
"    </a>",
"    ]. The efficacy of this drug may be related to inhibition of the binding of substance P (a mediator of pruritus) to the neurokinin receptor. A major drawback for its use is its high cost. Additional studies are necessary to determine the role of aprepitant in the management of patients with pruritus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H615716\">",
"    <span class=\"h2\">",
"     Immunosuppressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oral immunosuppressants,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil have demonstrated antipruritic effects in patients with atopic dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/65\">",
"     65",
"    </a>",
"    ]. The efficacy of these agents is most likely related to their antiinflammatory properties. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44457?source=see_link&amp;anchor=H17#H17\">",
"     \"Management of severe refractory atopic dermatitis (eczema)\", section on 'Systemic immunosuppressants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354466\">",
"    <span class=\"h2\">",
"     Phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phototherapy with ultraviolet radiation is a nonpharmacologic option for the treatment of pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/66\">",
"     66",
"    </a>",
"    ]. Although phototherapy has been most extensively used for skin lesion resolution in inflammatory dermatoses, such as psoriasis, it may also improve pruritus in the absence of a primary skin disease, such as in cases of prurigo nodularis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/67-69\">",
"     67-69",
"    </a>",
"    ], uremia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/70-72\">",
"     70-72",
"    </a>",
"    ], polycythemia vera [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/73,74\">",
"     73,74",
"    </a>",
"    ], psychogenic excoriations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/75\">",
"     75",
"    </a>",
"    ], and notalgia paresthetica [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/76\">",
"     76",
"    </a>",
"    ]. The mechanism through which ultraviolet light reduces pruritus is unknown, but may involve effects on epidermal opioid systems, epidermal cytokines, cutaneous mast cells, or epidermal nerve fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/36,72\">",
"     36,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple forms of phototherapy have been used for pruritus, including broad band UVB, narrow band UVB, psoralen plus UVA (PUVA), and UVA1. The efficacies of specific types of phototherapy vary among different disorders and individual patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/66,77,78\">",
"     66,77,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advantages of phototherapy include the ability to use it in patients with contraindications to systemic agents, such as some elderly patients taking multiple medications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/79\">",
"     79",
"    </a>",
"    ]. Potential side effects include skin burning or blistering, and a potential increase in risk for skin cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354473\">",
"    <span class=\"h2\">",
"     Future therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential future therapies for pruritus include inhibitors of IL-31 (a cytokine that has been implicated in pruritus in mice and has been found at increased levels in patients with atopic dermatitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/80,81\">",
"     80,81",
"    </a>",
"    ], a topical preparation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/82\">",
"     82",
"    </a>",
"    ], topical cannabinoids [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/83,84\">",
"     83,84",
"    </a>",
"    ], and prostanoid [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/85\">",
"     85",
"    </a>",
"    ] or H4 receptor antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354480\">",
"    <span class=\"h1\">",
"     APPROACH TO SPECIFIC TYPES OF PRURITUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical setting in which pruritus occurs influences the approach to treatment, and the initial step in the treatment of patients of pruritus should be identification of the underlying cause. Treatments that are efficacious for one form of pruritus may be insufficiently helpful in other situations. (See",
"    <a class=\"local\" href=\"#H8354354\">",
"     'Therapeutic options'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354487\">",
"    <span class=\"h2\">",
"     Dermatological disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of the underlying skin disorder is the primary focus in the management of pruritus secondary to dermatologic disorders. For example, pruritus often can be easily eradicated when due to curable conditions such as dermatophyte infections, pediculosis, or scabies. One of the most common causes of pruritus, xerosis (dry skin), can often be markedly improved with a few simple interventions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10090?source=see_link&amp;anchor=H690795#H690795\">",
"     \"Pruritus: Etiology and patient evaluation\", section on 'Xerosis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8354494\">",
"     'Xerosis (dry skin)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In contrast, the treatment of chronic disorders with cutaneous features, such as atopic dermatitis or chronic urticaria, often requires long-term therapy, and the suppression of symptoms can be challenging. The clinical manifestations and treatment of specific dermatologic disorders that present with pruritus are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10090?source=see_link&amp;anchor=H690788#H690788\">",
"     \"Pruritus: Etiology and patient evaluation\", section on 'Dermatologic disorders'",
"    </a>",
"    ). Xerosis and lichen simplex chronicus are briefly discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354494\">",
"    <span class=\"h3\">",
"     Xerosis (dry skin)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xerosis is common in the elderly and in people living in northern climates where home heating during the winter results in very low relative humidity. Interventions that may improve xerosis and related pruritus include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/88\">",
"     88",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Use of mild cleansers &ndash;",
"      </strong>",
"      Traditional soaps (eg, Ivory&reg;, Dial&reg;, Irish Spring&reg;, Zest&reg;) alkalinize the skin and can cause damage to the natural skin moisture barrier, thereby worsening xerosis and aggravating pruritus. Synthetic detergent (syndet) cleansers (eg, Dove&reg;, Olay&reg;, Cetaphil&reg;) or other mild cleansers are preferred. Syndet cleansers typically have a low pH that approximates the normal acidic pH of the skin. They tend to be less irritating than traditional soaps and may optimize skin barrier function [",
"      <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/89,90\">",
"       89,90",
"      </a>",
"      ]. In addition, there is some evidence to suggest that serine proteases involved in the pathogenesis of pruritus are inhibited by low pH agents [",
"      <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Routine use of skin moisturizers &ndash;",
"      </strong>",
"      Daily use of moisturizers, which contain substances that promote epidermal hydration (humectants such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/32/14852?source=see_link\">",
"       glycerin",
"      </a>",
"      , lactic acid, or urea)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      substances that reduce water loss from the skin (occlusives such as petrolatum) are crucial components of xerosis management [",
"      <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/92,93\">",
"       92,93",
"      </a>",
"      ]. Moisturizers",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      occlusives should be applied immediately after bathing and gentle drying of the skin.",
"      <br/>",
"      <br/>",
"      Thicker, greasier products tend to be more effective for maintaining skin moisture, but may be perceived as uncomfortable or unsightly by some patients. Greasier preparations may be better accepted by patients for use at bedtime.",
"     </li>",
"     <li>",
"      <strong>",
"       Avoidance of excessive and aggressive skin washing &ndash;",
"      </strong>",
"      Excessive washing can worsen dry skin, particularly when hot water is used to bathe. Lukewarm or warm water is preferable for bathing, and patients should be instructed to avoid aggressive scrubbing of the skin.",
"     </li>",
"     <li>",
"      <strong>",
"       Use of a humidifier &ndash;",
"      </strong>",
"      Increasing the relative humidity of indoor air during the winter may be beneficial for patients who are prone to xerosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, low pH topical agents may be of further benefit through their reduction in activity of serine proteases such as mast cell tryptase which is known to activate protease-activating receptor 2 (PAR",
"    <sub>",
"     2",
"    </sub>",
"    ) on skin nerve fibers. This notion stems from recent studies suggesting serine proteases, via PAR",
"    <sub>",
"     2",
"    </sub>",
"    located on C fiber terminals, may play an important role in mediating pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who develop eczema as a result of xerosis, moderate potency topical corticosteroids (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 2",
"    </a>",
"    ) can be used in combination with moisturizers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354501\">",
"    <span class=\"h3\">",
"     Lichen simplex chronicus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lichen simplex chronicus is a secondary skin disorder that results from excessive scratching. Lichenified plaques and excoriations are typically present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10090?source=see_link&amp;anchor=H690830#H690830\">",
"     \"Pruritus: Etiology and patient evaluation\", section on 'Lichen simplex chronicus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of lichen simplex chronicus centers of the discontinuation of the itch-scratch cycle. Commonly used therapies include topical corticosteroids under occlusion and intralesional corticosteroids. Although its use has not been specifically studied, the addition of 6% salicylic acid gel to topical corticosteroid therapy may offer benefit due to anti-prostanoid effects; topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    appeared to relieve the associated pruritus in one small randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/95\">",
"     95",
"    </a>",
"    ]. Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    has been reported to improve pruritus in a few patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354508\">",
"    <span class=\"h2\">",
"     Systemic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple systemic diseases may present with pruritus. Pruritus may respond to treatment of the underlying disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10090?source=see_link&amp;anchor=H690865#H690865\">",
"     \"Pruritus: Etiology and patient evaluation\", section on 'Systemic disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of pruritus associated with malignancy is best aimed at treating the underlying disease. Traditional antihistamines are largely ineffective.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     Paroxetine",
"    </a>",
"    or low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    may be of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/50,51,54,97,98\">",
"     50,51,54,97,98",
"    </a>",
"    ], and early studies suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    may also be of value. (See",
"    <a class=\"local\" href=\"#H8354438\">",
"     'Antidepressants'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8354459\">",
"     'Aprepitant'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients with pruritus related to polycythemia vera, lowering red cell mass via phlebotomy occasionally relieves symptoms, although in many instances aggressive treatment of the disease fails to control pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28554?source=see_link&amp;anchor=H26#H26\">",
"     \"Prognosis and treatment of polycythemia vera\", section on 'Pruritus'",
"    </a>",
"    .) Improvement in paroxysmal pruritus associated with multiple sclerosis during treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    has been documented in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. Therapies for pruritus due to mastocytosis, cholestasis, and uremia are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41767?source=see_link\">",
"     \"Treatment and prognosis of cutaneous mastocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39817?source=see_link\">",
"     \"Treatment and prognosis of systemic mastocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6937?source=see_link\">",
"     \"Uremic pruritus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23863?source=see_link\">",
"     \"Pruritus associated with cholestasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354515\">",
"    <span class=\"h2\">",
"     Peripheral neuropathic itch",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of treatments have been used for brachioradial pruritus, notalgia paresthetica, and post herpetic itch. Data on the treatment of these disorders are limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354522\">",
"    <span class=\"h3\">",
"     Brachioradial pruritus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical therapies may be useful for the treatment of brachioradial pruritus. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    led to improvement in 13 out of 15 patients in an open-label study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/15\">",
"     15",
"    </a>",
"    ] and in four out of seven patients in a small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/16\">",
"     16",
"    </a>",
"    ]. However, a randomized trial of 24 patients showed no benefit of capsaicin over a placebo cream. Topical 1% menthol may offer some relief [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/103\">",
"     103",
"    </a>",
"    ]. Topical corticosteroids are not effective [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/104,105\">",
"     104,105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the commercially available topical therapies mentioned above, use of a compounded cream containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    has been associated with complete or significant improvement in brachioradial pruritus in at least three patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/106\">",
"     106",
"    </a>",
"    ]. Additional studies are necessary to explore the efficacy and safety of topical amitriptyline-ketamine. Systemic administration of ketamine has been associated with multiple side effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40935?source=see_link\">",
"     \"Ketamine poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    First line options for oral therapy in patients who do not respond to local therapies include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/107-110\">",
"     107-110",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/111\">",
"     111",
"    </a>",
"    ]. Improvement with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/36/43592?source=see_link\">",
"     ketoprofen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/112\">",
"     112",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/113\">",
"     113",
"    </a>",
"    ] has also been documented in case reports.",
"   </p>",
"   <p>",
"    Surgical intervention is an option for patients with severe, intractable symptoms who fail to improve with other therapies. Cervical spine manipulation helped 10 out of 14 patients in one retrospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/114\">",
"     114",
"    </a>",
"    ]. Patients who have undergone surgical intervention for treatment of cervical tumor or disc herniation also have reported relief of pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/103,115\">",
"     103,115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354529\">",
"    <span class=\"h3\">",
"     Notalgia paresthetica",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    has been used for the management of notalgia paresthetica [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/17,18,116\">",
"     17,18,116",
"    </a>",
"    ]. In a randomized cross-over trial of 20 patients, more patients improved with topical capsaicin therapy than with vehicle (70 versus 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/17\">",
"     17",
"    </a>",
"    ]. However, symptoms returned after the cessation of therapy.",
"   </p>",
"   <p>",
"    The efficacy of topical anesthetics for notalgia paresthetica has not been formally studied, but improvement has been reported in a few patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/33\">",
"     33",
"    </a>",
"    ]. Systemic therapies for this disorder have included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    , which led to varying amounts of improvement in four patients in a case series [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/117\">",
"     117",
"    </a>",
"    ], and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/118\">",
"     118",
"    </a>",
"    ]. Botulinum toxin A and a paravertebral nerve block have also been effective in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/119,120\">",
"     119,120",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Nonpharmacologic therapies may be useful. In an observational study, transcutaneous electrical nerve stimulation led to a significant decrease in the pruritus score among 15 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/121\">",
"     121",
"    </a>",
"    ]. Additionally, in a case series, four out of six patients with notalgia paresthetica and abnormalities on spinal X-ray (dorsal arthrosis or spinal static disequilibrium) improved with physiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354536\">",
"    <span class=\"h3\">",
"     Postherpetic itch",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes zoster may result in severe, prolonged pruritus that persists after resolution of the acute disease. The best approach to treatment of postherpetic itch has not been established. Symptoms may or may not respond to treatments for postherpetic neuralgia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21608?source=see_link\">",
"     \"Postherpetic neuralgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Topical anesthetics are often used for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/58/6058/abstract/111\">",
"     111",
"    </a>",
"    ]. The efficacy of other agents used for neuropathic pruritus such as topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    , and tricyclic antidepressants are unknown. Antihistamines and topical corticosteroids are ineffective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8354543\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pruritus is a common symptom that can be incapacitating in severe cases. A wide variety of therapies have been utilized for management (",
"      <a class=\"graphic graphic_table graphicRef50432 graphicRef63221 \" href=\"UTD.htm?1/33/1566\">",
"       table 1A-B",
"      </a>",
"      ); however, data are limited on the efficacy of most treatments. (See",
"      <a class=\"local\" href=\"#H8354354\">",
"       'Therapeutic options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial step in the management of patients with pruritus is the identification of the inciting cause. In some cases, treatment of the underlying disorder results in the resolution of pruritus. However, in idiopathic or chronic disease, treatment is often challenging. (See",
"      <a class=\"local\" href=\"#H8354480\">",
"       'Approach to specific types of pruritus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Focal pruritus can often be managed with local therapies, such as topical corticosteroids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"       capsaicin",
"      </a>",
"      , topical calcineurin inhibitors, topical anesthetics, and topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"       doxepin",
"      </a>",
"      . Topical corticosteroids should only be used for patients with inflammatory dermatoses. (See",
"      <a class=\"local\" href=\"#H8354368\">",
"       'Local pharmacologic therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measures to minimize skin dryness and irritation are important components of the management of all patients with generalized pruritus. Skin should be gently cleansed and frequently moisturized. Irritating environmental factors should be avoided. Stress reduction may also be useful. (See",
"      <a class=\"local\" href=\"#H8354361\">",
"       'Nonpharmacologic interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with generalized pruritus that is not relieved by nonpharmacologic interventions often require systemic agents for symptom control. The efficacy of oral antihistamines for pruritus in disorders other than urticaria and mastocytosis is uncertain. However, the relative safety, low cost, and wide availability of these agents make them reasonable choices for first-line therapy. The soporific effects of sedating first generation antihistamines may be of particular benefit in patient with nocturnal pruritus. (See",
"      <a class=\"local\" href=\"#H8354410\">",
"       'Systemic therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Agents that act through effects on the central nervous system are additional options for the treatment of pruritus. Modulators of opioid receptors, antidepressants, anticonvulsants, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/28/33222?source=see_link\">",
"       aprepitant",
"      </a>",
"      have been used successfully. (See",
"      <a class=\"local\" href=\"#H8354410\">",
"       'Systemic therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/1\">",
"      van Os-Medendorp H, Ros WJ, Eland-de Kok PC, et al. Effectiveness of the nursing programme 'Coping with itch': a randomized controlled study in adults with chronic pruritic skin disease. Br J Dermatol 2007; 156:1235.",
"     </a>",
"    </li>",
"    <li>",
"     Gieler U, Niemeier V, Brosig B, Kupfer J. Psychosomatic aspects of pruritus. In: Itch: Basic Mechanisms and Therapy, Yosipovitch G, Greaves MW, Fleischer AB Jr, McGlone F (Eds), Marcel Dekker, New York 2004. p.343.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/3\">",
"      Yamamoto Y, Yamazaki S, Hayashino Y, et al. Association between frequency of pruritic symptoms and perceived psychological stress: a Japanese population-based study. Arch Dermatol 2009; 145:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/4\">",
"      Yosipovitch G, Goon A, Wee J, et al. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000; 143:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/5\">",
"      Yosipovitch G, Goon AT, Wee J, et al. Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus. Int J Dermatol 2002; 41:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/6\">",
"      Pfab F, Huss-Marp J, Gatti A, et al. Influence of acupuncture on type I hypersensitivity itch and the wheal and flare response in adults with atopic eczema - a blinded, randomized, placebo-controlled, crossover trial. Allergy 2010; 65:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/7\">",
"      Kim KH, Lee MS, Choi SM. Acupuncture for treating uremic pruritus in patients with end-stage renal disease: a systematic review. J Pain Symptom Manage 2010; 40:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/8\">",
"      Tuerk MJ, Koo J. A practical review and update on the management of pruritus sine materia. Cutis 2008; 82:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/9\">",
"      Bingham LG, Noble JW, Davis MD. Wet dressings used with topical corticosteroids for pruritic dermatoses: A retrospective study. J Am Acad Dermatol 2009; 60:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/10\">",
"      Devillers AC, de Waard-van der Spek FB, Mulder PG, Oranje AP. Treatment of refractory atopic dermatitis using 'wet-wrap' dressings and diluted corticosteroids: results of standardized treatment in both children and adults. Dermatology 2002; 204:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/11\">",
"      Papoiu AD, Yosipovitch G. Topical capsaicin. The fire of a 'hot' medicine is reignited. Expert Opin Pharmacother 2010; 11:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/12\">",
"      Cassano N, Tessari G, Vena GA, Girolomoni G. Chronic pruritus in the absence of specific skin disease: an update on pathophysiology, diagnosis, and therapy. Am J Clin Dermatol 2010; 11:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/13\">",
"      Knotkova H, Pappagallo M, Szallasi A. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival? Clin J Pain 2008; 24:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/14\">",
"      Gooding SM, Canter PH, Coelho HF, et al. Systematic review of topical capsaicin in the treatment of pruritus. Int J Dermatol 2010; 49:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/15\">",
"      Knight TE, Hayashi T. Solar (brachioradial) pruritus--response to capsaicin cream. Int J Dermatol 1994; 33:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/16\">",
"      Barry R, Rogers S. Brachioradial pruritus--an enigmatic entity. Clin Exp Dermatol 2004; 29:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/17\">",
"      Wallengren J, Klinker M. Successful treatment of notalgia paresthetica with topical capsaicin: vehicle-controlled, double-blind, crossover study. J Am Acad Dermatol 1995; 32:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/18\">",
"      Leibsohn E. Treatment of notalgia paresthetica with capsaicin. Cutis 1992; 49:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/19\">",
"      Makhlough A, Ala S, Haj-Heydari Z, et al. Topical capsaicin therapy for uremic pruritus in patients on hemodialysis. Iran J Kidney Dis 2010; 4:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/20\">",
"      Lotti T, Teofoli P, Tsampau D. Treatment of aquagenic pruritus with topical capsaicin cream. J Am Acad Dermatol 1994; 30:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/21\">",
"      Breneman DL, Cardone JS, Blumsack RF, et al. Topical capsaicin for treatment of hemodialysis-related pruritus. J Am Acad Dermatol 1992; 26:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/22\">",
"      St&auml;nder S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol 2001; 44:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/23\">",
"      Yosipovitch G, Maibach HI, Rowbotham MC. Effect of EMLA pre-treatment on capsaicin-induced burning and hyperalgesia. Acta Derm Venereol 1999; 79:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/24\">",
"      Fleischer AB Jr, Boguniewicz M. An approach to pruritus in atopic dermatitis: a critical systematic review of the tacrolimus ointment literature. J Drugs Dermatol 2010; 9:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/25\">",
"      St&auml;nder S, Sch&uuml;rmeyer-Horst F, Luger TA, Weisshaar E. Treatment of pruritic diseases with topical calcineurin inhibitors. Ther Clin Risk Manag 2006; 2:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/26\">",
"      Pereira U, Boulais N, Lebonvallet N, et al. Mechanisms of the sensory effects of tacrolimus on the skin. Br J Dermatol 2010; 163:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/27\">",
"      Yosipovitch G, Maibach HI. Effect of topical pramoxine on experimentally induced pruritus in humans. J Am Acad Dermatol 1997; 37:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/28\">",
"      Shuttleworth D, Hill S, Marks R, Connelly DM. Relief of experimentally induced pruritus with a novel eutectic mixture of local anaesthetic agents. Br J Dermatol 1988; 119:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/29\">",
"      Gal-Oz A, Rogowski O, Swartzon M, Kivity S. Ethyl chloride as an antipruritic agent: a double-blind placebo-controlled prospective study. Dermatology 2010; 221:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/30\">",
"      Young TA, Patel TS, Camacho F, et al. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. J Dermatolog Treat 2009; 20:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/31\">",
"      Kopecky EA, Jacobson S, Bch MB, et al. Safety and pharmacokinetics of EMLA in the treatment of postburn pruritus in pediatric patients: a pilot study. J Burn Care Rehabil 2001; 22:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/32\">",
"      FREEMAN CW. A new topical remedy useful in the management of pruritus. J Natl Med Assoc 1961; 53:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/33\">",
"      Layton AM, Cotterill JA. Notalgia paraesthetica--report of three cases and their treatment. Clin Exp Dermatol 1991; 16:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/34\">",
"      Freitag G, H&ouml;ppner T. Results of a postmarketing drug monitoring survey with a polidocanol-urea preparation for dry, itching skin. Curr Med Res Opin 1997; 13:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/35\">",
"      Eschler DC, Klein PA. An evidence-based review of the efficacy of topical antihistamines in the relief of pruritus. J Drugs Dermatol 2010; 9:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/36\">",
"      Metz M, St&auml;nder S. Chronic pruritus--pathogenesis, clinical aspects and treatment. J Eur Acad Dermatol Venereol 2010; 24:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/37\">",
"      Greene SL, Reed CE, Schroeter AL. Double-blind crossover study comparing doxepin with diphenhydramine for the treatment of chronic urticaria. J Am Acad Dermatol 1985; 12:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/38\">",
"      O'Donoghue M, Tharp MD. Antihistamines and their role as antipruritics. Dermatol Ther 2005; 18:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/39\">",
"      Klein PA, Clark RA. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999; 135:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/40\">",
"      Raap U, St&auml;nder S, Metz M. Pathophysiology of itch and new treatments. Curr Opin Allergy Clin Immunol 2011; 11:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/41\">",
"      Phan NQ, Bernhard JD, Luger TA, St&auml;nder S. Antipruritic treatment with systemic &mu;-opioid receptor antagonists: a review. J Am Acad Dermatol 2010; 63:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/42\">",
"      Penning JP, Samson B, Baxter AD. Reversal of epidural morphine-induced respiratory depression and pruritus with nalbuphine. Can J Anaesth 1988; 35:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/43\">",
"      Peer G, Kivity S, Agami O, et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 1996; 348:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/44\">",
"      Pauli-Magnus C, Mikus G, Alscher DM, et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 2000; 11:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/45\">",
"      Yuan CS, Foss JF, O'Connor M, et al. Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine. Drug Alcohol Depend 1998; 52:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/46\">",
"      Moss J, Rosow CE. Development of peripheral opioid antagonists' new insights into opioid effects. Mayo Clin Proc 2008; 83:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/47\">",
"      Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 2006; 54:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/48\">",
"      Kumagai H, Ebata T, Takamori K, et al. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 2010; 25:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/49\">",
"      Wang H, Yosipovitch G. New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma. Int J Dermatol 2010; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/50\">",
"      Davis MP, Frandsen JL, Walsh D, et al. Mirtazapine for pruritus. J Pain Symptom Manage 2003; 25:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/51\">",
"      Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol 2004; 50:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/52\">",
"      Demierre MF, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J Am Acad Dermatol 2006; 55:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/53\">",
"      Sheen MJ, Ho ST, Lee CH, et al. Prophylactic mirtazapine reduces intrathecal morphine-induced pruritus. Br J Anaesth 2008; 101:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/54\">",
"      St&auml;nder S, B&ouml;ckenholt B, Sch&uuml;rmeyer-Horst F, et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol 2009; 89:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/55\">",
"      Mayo MJ, Handem I, Saldana S, et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007; 45:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/56\">",
"      Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2003; 98:2736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/57\">",
"      Yesudian PD, Wilson NJ. Efficacy of gabapentin in the management of pruritus of unknown origin. Arch Dermatol 2005; 141:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/58\">",
"      Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Engl J Med 2009; 361:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/59\">",
"      St&auml;nder S, Siepmann D, Herrgott I, et al. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 2010; 5:e10968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/60\">",
"      Vincenzi B, Fratto ME, Santini D, Tonini G. Aprepitant against pruritus in patients with solid tumours. Support Care Cancer 2010; 18:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/61\">",
"      Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritus. N Engl J Med 2010; 363:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/62\">",
"      Mir O, Blanchet B, Goldwasser F. More on aprepitant for erlotinib-induced pruritus. N Engl J Med 2011; 364:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/63\">",
"      Booken N, Heck M, Nicolay JP, et al. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol 2011; 164:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/64\">",
"      Torres T, Fernandes I, Selores M, et al. Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues. J Am Acad Dermatol 2012; 66:e14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/65\">",
"      Patel T, Yosipovitch G. Therapy of pruritus. Expert Opin Pharmacother 2010; 11:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/66\">",
"      Rivard J, Lim HW. Ultraviolet phototherapy for pruritus. Dermatol Ther 2005; 18:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/67\">",
"      Hammes S, Hermann J, Roos S, Ockenfels HM. UVB 308-nm excimer light and bath PUVA: combination therapy is very effective in the treatment of prurigo nodularis. J Eur Acad Dermatol Venereol 2011; 25:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/68\">",
"      Bruni E, Caccialanza M, Piccinno R. Phototherapy of generalized prurigo nodularis. Clin Exp Dermatol 2010; 35:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/69\">",
"      Tamagawa-Mineoka R, Katoh N, Ueda E, Kishimoto S. Narrow-band ultraviolet B phototherapy in patients with recalcitrant nodular prurigo. J Dermatol 2007; 34:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/70\">",
"      Ada S, Se&ccedil;kin D, Budakolu I, Ozdemir FN. Treatment of uremic pruritus with narrowband ultraviolet B phototherapy: an open pilot study. J Am Acad Dermatol 2005; 53:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/71\">",
"      Gilchrest BA, Rowe JW, Brown RS, et al. Relief of uremic pruritus with ultraviolet phototherapy. N Engl J Med 1977; 297:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/72\">",
"      Ko MJ, Yang JY, Wu HY, et al. Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial. Br J Dermatol 2011; 165:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/73\">",
"      Madkan VK, Bandow GD, Koo JY. Resolution of pruritus secondary to polycythemia vera in a patient treated with narrow-band ultraviolet B phototherapy. J Dermatolog Treat 2005; 16:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/74\">",
"      Baldo A, Sammarco E, Plaitano R, et al. Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera. Br J Dermatol 2002; 147:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/75\">",
"      Ozden MG, Aydin F, Sent&uuml;rk N, et al. Narrow-band ultraviolet B as a potential alternative treatment for resistant psychogenic excoriation: an open-label study. Photodermatol Photoimmunol Photomed 2010; 26:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/76\">",
"      P&eacute;rez-P&eacute;rez L, Allegue F, Fabeiro JM, et al. Notalgia paresthesica successfully treated with narrow-band UVB: report of five cases. J Eur Acad Dermatol Venereol 2010; 24:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/77\">",
"      Hsu MM, Yang CC. Uraemic pruritus responsive to broadband ultraviolet (UV) B therapy does not readily respond to narrowband UVB therapy. Br J Dermatol 2003; 149:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/78\">",
"      Gambichler T, Hyun J, Sommer A, et al. A randomised controlled trial on photo(chemo)therapy of subacute prurigo. Clin Exp Dermatol 2006; 31:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/79\">",
"      Patel T, Yosipovitch G. The management of chronic pruritus in the elderly. Skin Therapy Lett 2010; 15:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/80\">",
"      Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006; 117:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/81\">",
"      Grimstad O, Sawanobori Y, Vestergaard C, et al. Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis. Exp Dermatol 2009; 18:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/82\">",
"      Bigliardi PL, Stammer H, Jost G, et al. Treatment of pruritus with topically applied opiate receptor antagonist. J Am Acad Dermatol 2007; 56:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/83\">",
"      Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol 2008; 22:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/84\">",
"      St&auml;nder S, Reinhardt HW, Luger TA. [Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus]. Hautarzt 2006; 57:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/85\">",
"      Arai I, Takaoka A, Hashimoto Y, et al. Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis in mice. Eur J Pharmacol 2007; 556:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/86\">",
"      Engelhardt H, Smits RA, Leurs R, et al. A new generation of anti-histamines: Histamine H4 receptor antagonists on their way to the clinic. Curr Opin Drug Discov Devel 2009; 12:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/87\">",
"      Dunford PJ, Williams KN, Desai PJ, et al. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol 2007; 119:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/88\">",
"      White-Chu EF, Reddy M. Dry skin in the elderly: complexities of a common problem. Clin Dermatol 2011; 29:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/89\">",
"      Boccanfuso SM, Cosmet L, Volpe AR, Bensel A. Skin xerosis. Clinical report on the effect of a moisturizing soap bar. Cutis 1978; 21:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/90\">",
"      Abbas S, Goldberg JW, Massaro M. Personal cleanser technology and clinical performance. Dermatol Ther 2004; 17 Suppl 1:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/91\">",
"      Steinhoff M, Neisius U, Ikoma A, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 2003; 23:6176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/92\">",
"      Lod&eacute;n M. The clinical benefit of moisturizers. J Eur Acad Dermatol Venereol 2005; 19:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/93\">",
"      Draelos ZD. Active agents in common skin care products. Plast Reconstr Surg 2010; 125:719.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical Dermatology: A Color Guide to Diagnosis and Therapy, 4th ed, Habif TP (Ed), Mosby, St. Louis 2004. p.60.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/95\">",
"      Yosipovitch G, Sugeng MW, Chan YH, et al. The effect of topically applied aspirin on localized circumscribed neurodermatitis. J Am Acad Dermatol 2001; 45:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/96\">",
"      Gencoglan G, Inanir I, Gunduz K. Therapeutic hotline: Treatment of prurigo nodularis and lichen simplex chronicus with gabapentin. Dermatol Ther 2010; 23:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/97\">",
"      Aymard JP, Lederlin P, Witz F, et al. Cimetidine for pruritus in Hodgkin's disease. Br Med J 1980; 280:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/98\">",
"      Zylicz Z, Krajnik M, Sorge AA, Costantini M. Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. J Pain Symptom Manage 2003; 26:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/99\">",
"      Etter L, Myers SA. Pruritus in systemic disease: mechanisms and management. Dermatol Clin 2002; 20:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/100\">",
"      Saini KS, Patnaik MM, Tefferi A. Polycythemia vera-associated pruritus and its management. Eur J Clin Invest 2010; 40:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/101\">",
"      Osterman PO. Paroxysmal itching in multiple sclerosis. Br J Dermatol 1976; 95:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/102\">",
"      Yamamoto M, Yabuki S, Hayabara T, Otsuki S. Paroxysmal itching in multiple sclerosis: a report of three cases. J Neurol Neurosurg Psychiatry 1981; 44:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/103\">",
"      Yosipovitch G, Samuel LS. Neuropathic and psychogenic itch. Dermatol Ther 2008; 21:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/104\">",
"      Wallengren J. Brachioradial pruritus: a recurrent solar dermopathy. J Am Acad Dermatol 1998; 39:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/105\">",
"      Heyl T. Brachioradial pruritus. Arch Dermatol 1983; 119:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/106\">",
"      Poterucha TJ, Murphy SL, Davis MD, et al. Topical amitriptyline-ketamine for the treatment of brachioradial pruritus. JAMA Dermatol 2013; 149:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/107\">",
"      Bueller HA, Bernhard JD, Dubroff LM. Gabapentin treatment for brachioradial pruritus. J Eur Acad Dermatol Venereol 1999; 13:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/108\">",
"      Winhoven SM, Coulson IH, Bottomley WW. Brachioradial pruritus: response to treatment with gabapentin. Br J Dermatol 2004; 150:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/109\">",
"      Kanitakis J. Brachioradial pruritus: report of a new case responding to gabapentin. Eur J Dermatol 2006; 16:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/110\">",
"      Mataix J, Silvestre JF, Climent JM, et al. [Brachioradial pruritus as a symptom of cervical radiculopathy]. Actas Dermosifiliogr 2008; 99:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/111\">",
"      Wood GJ, Akiyama T, Carstens E, et al. An insatiable itch. J Pain 2009; 10:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/112\">",
"      Abbott LG. Neuropathic pruritus. Australas J Dermatol 1998; 39:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/113\">",
"      Crevits L. Brachioradial pruritus--a peculiar neuropathic disorder. Clin Neurol Neurosurg 2006; 108:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/114\">",
"      Tait CP, Grigg E, Quirk CJ. Brachioradial pruritus and cervical spine manipulation. Australas J Dermatol 1998; 39:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/115\">",
"      Binder A, F&ouml;lster-Holst R, Sahan G, et al. A case of neuropathic brachioradial pruritus caused by cervical disc herniation. Nat Clin Pract Neurol 2008; 4:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/116\">",
"      Metz M, Krause K, Maurer M, Magerl M. Treatment of notalgia paraesthetica with an 8% capsaicin patch. Br J Dermatol 2011; 165:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/117\">",
"      Savk E, Bolukbasi O, Akyol A, Karaman G. Open pilot study on oxcarbazepine for the treatment of notalgia paresthetica. J Am Acad Dermatol 2001; 45:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/118\">",
"      Loosemore MP, Bordeaux JS, Bernhard JD. Gabapentin treatment for notalgia paresthetica, a common isolated peripheral sensory neuropathy. J Eur Acad Dermatol Venereol 2007; 21:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/119\">",
"      Weinfeld PK. Successful treatment of notalgia paresthetica with botulinum toxin type A. Arch Dermatol 2007; 143:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/120\">",
"      Goulden V, Toomey PJ, Highet AS. Successful treatment of notalgia paresthetica with a paravertebral local anesthetic block. J Am Acad Dermatol 1998; 38:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/121\">",
"      Savk E, Savk O, Sendur F. Transcutaneous electrical nerve stimulation offers partial relief in notalgia paresthetica patients with a relevant spinal pathology. J Dermatol 2007; 34:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/58/6058/abstract/122\">",
"      Raison-Peyron N, Meunier L, Acevedo M, Meynadier J. Notalgia paresthetica: clinical, physiopathological and therapeutic aspects. A study of 12 cases. J Eur Acad Dermatol Venereol 1999; 12:215.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5576 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-FD0A04FE88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_58_6058=[""].join("\n");
var outline_f5_58_6058=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8354543\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8354347\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8354354\">",
"      THERAPEUTIC OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8354361\">",
"      Nonpharmacologic interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8354368\">",
"      Local pharmacologic therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8354375\">",
"      - Topical and intralesional corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8354382\">",
"      - Topical capsaicin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8354389\">",
"      - Topical calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8354396\">",
"      - Topical anesthetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8354403\">",
"      - Topical antihistamines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8354410\">",
"      Systemic therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8354417\">",
"      - Antihistamines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8354424\">",
"      - Opioid receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8354431\">",
"      - Opioid receptor agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8354438\">",
"      - Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8354445\">",
"      - Anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8354459\">",
"      - Aprepitant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H615716\">",
"      Immunosuppressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8354466\">",
"      Phototherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8354473\">",
"      Future therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8354480\">",
"      APPROACH TO SPECIFIC TYPES OF PRURITUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8354487\">",
"      Dermatological disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8354494\">",
"      - Xerosis (dry skin)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8354501\">",
"      - Lichen simplex chronicus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8354508\">",
"      Systemic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8354515\">",
"      Peripheral neuropathic itch",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8354522\">",
"      - Brachioradial pruritus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8354529\">",
"      - Notalgia paresthetica",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8354536\">",
"      - Postherpetic itch",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8354543\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5576\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5576|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/51/25404\" title=\"table 1A\">",
"      Pruritus topical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/8/5261\" title=\"table 1B\">",
"      Pruritus systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 2\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=related_link\">",
"      Intralesional injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40935?source=related_link\">",
"      Ketamine poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44457?source=related_link\">",
"      Management of severe refractory atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=related_link\">",
"      New onset urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21608?source=related_link\">",
"      Postherpetic neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28554?source=related_link\">",
"      Prognosis and treatment of polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23863?source=related_link\">",
"      Pruritus associated with cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10090?source=related_link\">",
"      Pruritus: Etiology and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41767?source=related_link\">",
"      Treatment and prognosis of cutaneous mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39817?source=related_link\">",
"      Treatment and prognosis of systemic mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6937?source=related_link\">",
"      Uremic pruritus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_58_6059="SJSTEN risk HLA type";
var content_f5_58_6059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F76186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F76186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    HLA types associated with an increased risk of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) induced by specific drugs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug type yielding increased risk of SJS/TEN",
"       </td>",
"       <td class=\"subtitle1\">",
"        HLA type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfonamides",
"       </td>",
"       <td>",
"        HLA-A29, HLA-B12, HLA-DR7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxicam (an NSAID)",
"       </td>",
"       <td>",
"        HLA-A2, HLA-B12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbamazepine",
"       </td>",
"       <td>",
"        HLA-B*1502, HLA-A*3101",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allopurinol",
"       </td>",
"       <td>",
"        HLA-B*5801",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methazolamide (with ocular involvement)",
"       </td>",
"       <td>",
"        HLA-B59",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abacavir",
"       </td>",
"       <td>",
"        HLA-B*5701",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_58_6059=[""].join("\n");
var outline_f5_58_6059=null;
var title_f5_58_6060="Travelers diarrhea rx";
var content_f5_58_6060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Oral agents for self-treatment of travelers' diarrhea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Agent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Adult dose",
"      </td>",
"      <td class=\"subtitle1\">",
"       Pediatric dose&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Norfloxacin",
"      </td>",
"      <td>",
"       400 mg twice daily for up to three days",
"      </td>",
"      <td>",
"       Not recommended",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ciprofloxacin&loz;",
"      </td>",
"      <td>",
"       500 mg twice daily for up to three days",
"      </td>",
"      <td>",
"       20 to 30 mg/kg per day in two divided doses for up to three days; maximum dose 500 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ofloxacin&loz;",
"      </td>",
"      <td>",
"       200 mg twice daily for up to three days",
"      </td>",
"      <td>",
"       7.5 mg/kg every 12 hours for up to three days; maximum dose 200 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Levofloxacin&loz;",
"      </td>",
"      <td>",
"       500 mg once daily for up to three days",
"      </td>",
"      <td>",
"       10 mg/kg once daily for up to three days; maximum dose 500 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Azithromycin&sect;",
"      </td>",
"      <td>",
"       1000 mg single dose",
"      </td>",
"      <td>",
"       10 mg/kg once daily (single dose); maximum dose 1000 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rifaxamin",
"      </td>",
"      <td>",
"       200 mg three times daily for up to three days",
"      </td>",
"      <td>",
"       &ge;12 years: 200 mg three times daily for up to three days",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     &bull; Self-treatment of travelers' diarrhea in children is controversial.",
"     <br>",
"      &loz; Not licensed for this indication in children younger than 18 years.",
"      <br>",
"       &sect; Preferred agent for children.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Hill, DR, Ericsson, CD, Pearson, RD, et al. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1499.",
"     <br>",
"      Mackell, S. Traveler's diarrhea in the pediatric population: etiology and impact. Clin Infect Dis 2005; 41:S547.",
"      <br>",
"       Ang, JY. Traveler's diarrhea: Updates for pediatricians. Pediatr Ann 2008; 37:814.",
"       <br>",
"        Christenson, JC. Preparing families with children traveling to developing countries. Pediatr Ann 2008; 37:805.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_58_6060=[""].join("\n");
var outline_f5_58_6060=null;
var title_f5_58_6061="Aberrant receptor screen";
var content_f5_58_6061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F65003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F65003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    In vivo screening protocol to detect the presence of aberrant adrenal hormone receptors in adrenal Cushing's syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Time, min",
"       </td>",
"       <td class=\"subtitle1\">",
"        Day 1",
"       </td>",
"       <td class=\"subtitle1\">",
"        Day 2",
"       </td>",
"       <td class=\"subtitle1\">",
"        Day 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -60",
"       </td>",
"       <td>",
"        Fasting-supine",
"       </td>",
"       <td>",
"        Fasting-supine",
"       </td>",
"       <td>",
"        Fasting-supine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -15",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Upright *",
"       </td>",
"       <td>",
"        GnRH 100 microgram IV *",
"       </td>",
"       <td>",
"        Glucagon 1 mg IV *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +30",
"       </td>",
"       <td>",
"        Upright *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +60",
"       </td>",
"       <td>",
"        Upright *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +90",
"       </td>",
"       <td>",
"        Upright *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +120",
"       </td>",
"       <td>",
"        Upright *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +150",
"       </td>",
"       <td>",
"        Supine *",
"       </td>",
"       <td>",
"        (Meal)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +180",
"       </td>",
"       <td>",
"        Mixed meal *",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Vasopressin 10 IU IM *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +210",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +240",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +270",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +300",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        TRH 200 microgram IV *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +330",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +360",
"       </td>",
"       <td>",
"        ACTH 1-24 250 mircogram IV *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        Metoclopramide 10 mg orally *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +390",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +420",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +450",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +480",
"       </td>",
"       <td>",
"        *",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        *",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *: Blood samples for determination of cortisol, ACTH, other hormones, and vital signs.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lacroix A, Mircescu, Hamet P. Clinical evaluation of the presence of abnormal hormone receptors in adrenal Cushing's syndrome. The Endocrinologist 1999; 9:9. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_58_6061=[""].join("\n");
var outline_f5_58_6061=null;
var title_f5_58_6062="Approximate dose equivalents stimulants for ADHD";
var content_f5_58_6062=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dosing guidelines when switching from one stimulant to another in the treatment of attention deficit hyperactivity disorder in children and adolescents*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Current medication and dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        New medication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended starting dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Switching from one form of methylphenidate to another",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate IR",
"        <br/>",
"        5 mg twice daily or three times daily",
"       </td>",
"       <td>",
"        Methylphenidate osmotic release (Concerta&reg;)",
"       </td>",
"       <td>",
"        18 mg every morning",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate IR",
"        <br/>",
"        10 mg twice daily or three times daily",
"       </td>",
"       <td>",
"        Methylphenidate osmotic release",
"       </td>",
"       <td>",
"        36 mg every morning",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate IR",
"        <br/>",
"        15 mg twice daily or three times daily",
"       </td>",
"       <td>",
"        Methylphenidate osmotic release",
"       </td>",
"       <td>",
"        54 mg every morning",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate IR",
"        <br/>",
"        20 mg twice daily or three times daily",
"       </td>",
"       <td>",
"        Methylphenidate osmotic release",
"       </td>",
"       <td>",
"        72 mg every morning",
"       </td>",
"       <td>",
"        Conversion dosage should not exceed 72 mg per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate IR",
"       </td>",
"       <td>",
"        Dexmethylphenidate (Focalin&reg; or Focalin&reg; XR)",
"       </td>",
"       <td>",
"        One-half the current total daily dose",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate IR",
"        <br/>",
"        5 mg three times per day",
"       </td>",
"       <td>",
"        Methylphenidate patch (Daytrana&reg;)",
"       </td>",
"       <td>",
"        10 mg (12.5 cm",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        Methylphenidate patch has greater systemic bioavailability than oral preparations. Patients changing from oral methylphenidate IR doses &le;20 mg/day should be started on the 10 mg patch. Allow at least one week before increasing to the next higher patch strength, if needed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate IR",
"        <br/>",
"        7.5 mg three times per day",
"       </td>",
"       <td>",
"        Methylphenidate patch",
"       </td>",
"       <td>",
"        15 mg (18.75 cm",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate IR",
"        <br/>",
"        10 mg three times per day",
"       </td>",
"       <td>",
"        Methylphenidate patch",
"       </td>",
"       <td>",
"        20 mg (25 cm",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate IR",
"        <br/>",
"        15 mg three times per day",
"       </td>",
"       <td>",
"        Methylphenidate patch",
"       </td>",
"       <td>",
"        30 mg (37.5 cm",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate osmotic release",
"        <br/>",
"        18 mg",
"       </td>",
"       <td>",
"        Methylphenidate patch",
"       </td>",
"       <td>",
"        10 mg (12.5 cm",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate osmotic release",
"        <br/>",
"        27 mg",
"       </td>",
"       <td>",
"        Methylphenidate patch",
"       </td>",
"       <td>",
"        15 mg (18.75 cm",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate osmotic release",
"        <br/>",
"        36 mg",
"       </td>",
"       <td>",
"        Methylphenidate patch",
"       </td>",
"       <td>",
"        20 mg (25 cm",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate osmotic release",
"        <br/>",
"        54 mg",
"       </td>",
"       <td>",
"        Methylphenidate patch",
"       </td>",
"       <td>",
"        30 mg (37.5 cm",
"        <sup>",
"         2",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Switching to dextroamphetamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Any stimulant",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Dextroamphetamine or dextroamphetamine spansules",
"       </td>",
"       <td>",
"        5 mg once or twice per day",
"       </td>",
"       <td>",
"        Daily dosage may be increased in increments of 5 mg at weekly intervals until optimal response is obtained (maximum daily dose 40 mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Any stimulant",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Lisdexamfetamine (Vyvanse&reg;)",
"       </td>",
"       <td>",
"        30 mg once daily in the morning",
"       </td>",
"       <td>",
"        Daily dosage may be increased in increments of 10 or 20 mg at approximately weekly intervals until optimal response is obtained (maximum dose 70 mg/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Switching to amphetamine-dextroamphetamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amphetamine-dextroamphetamine (Adderall&reg;) IR",
"       </td>",
"       <td>",
"        Amphetamine-dextroamphetamine XR",
"       </td>",
"       <td>",
"        Same total daily dose",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Any stimulant other than amphetamine-dextroamphetamine IR",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        Amphetamine-dextroamphetamine XR",
"       </td>",
"       <td>",
"        6 to 12 years: 10 mg once daily in the morning",
"       </td>",
"       <td>",
"        Daily dosage may be adjusted in increments of 5 mg or 10 mg at weekly intervals until optimal response is obtained (maximum daily dose 30 mg/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13 to 17 years: 10 mg once daily",
"       </td>",
"       <td>",
"        Daily dosage may be increased to 20 mg/day after one week if symptoms are not adequately controlled",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IR: immediate release; XR: extended release.",
"     <br>",
"      * Ultimate dose must be individualized based upon patient needs and response.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       There are no reliable data to provide guidelines for switching between different classes of long-acting stimulants.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Daily Med, US product information:",
"        <a href=\"file://dailymed.nlm.nih.gov/dailymed/about.cfm\" target=\"_blank\">",
"         file://dailymed.nlm.nih.gov/dailymed/about.cfm",
"        </a>",
"        . Accessed on June 8, 2011.",
"       </li>",
"       <li>",
"        Arnold LE, Lindsay RL, L&oacute;pez FA, et al. Treating attention-deficit/hyperactivity disorder with a stimulant transdermal patch: the clinical art. Pediatrics 2007; 120:1100.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_58_6062=[""].join("\n");
var outline_f5_58_6062=null;
var title_f5_58_6063="Contents: General geriatrics";
var content_f5_58_6063=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?43/6/44141\">",
"       Geriatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       General geriatrics",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			General geriatrics",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Geriatric evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/19/3385\">",
"           Approach to the evaluation of older drivers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/3/8248\">",
"           Cervical cancer screening tests: Evidence of effectiveness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/38/43624\">",
"           Comprehensive geriatric assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/18/38186\">",
"           Geriatric health maintenance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/4/37962\">",
"           Overview of preventive medicine in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/58/24488\">",
"           Screening for abdominal aortic aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/33/22039\">",
"           Screening for bladder cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/49/41754\">",
"           Screening for breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/16/38154\">",
"           Screening for cervical cancer: Rationale and recommendations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/10/37034\">",
"           Screening for colorectal cancer: Strategies in patients at average risk",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/16/2312\">",
"           Screening for diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/58/28586\">",
"           Screening for lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/14/10474\">",
"           Screening for ovarian cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/8/42122\">",
"           Screening for prostate cancer",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Geriatric management",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/0/30730\">",
"           Drug prescribing for older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/12/31946\">",
"           Geriatric nutrition: Nutritional issues in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/61/15322\">",
"           Hospital management of older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/9/11417\">",
"           Managing multiple comorbidities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/9/42138\">",
"           Medical care of the nursing home patient in the United States",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/22/33130\">",
"           Overview of geriatric rehabilitation: Program components and settings for rehabilitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/60/9161\">",
"           Physical activity and exercise in older adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hearing loss",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/6/26727\">",
"           Etiology and diagnosis of tinnitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/15/10490\">",
"           Etiology of hearing loss in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/32/39429\">",
"           Evaluation of hearing loss in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/24/39300\">",
"           Hearing amplification in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/58/41896\">",
"           Presbycusis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/57/25495\">",
"           Treatment of tinnitus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/34/15913\">",
"           Accidental hypothermia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/43/23223\">",
"           Approach to the patient with dizziness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/35/2617\">",
"           Approach to the patient with weight loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/27/17850\">",
"           Elder mistreatment: Abuse, neglect, and financial exploitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/32/11786\">",
"           Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/26/34215\">",
"           Failure to thrive in elderly adults: Evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/29/42455\">",
"           Failure to thrive in elderly adults: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/4/22602\">",
"           Falls in older persons: Risk factors and patient evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/7/28792\">",
"           Frailty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/12/9417\">",
"           Gait disorders of elderly patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/31/18937\">",
"           Hip fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/58/33706\">",
"           Medical consultation for patients with hip fracture",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/20/34120\">",
"           Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/12/8393\">",
"           Prevention of falls and complications of falls in community-dwelling older persons",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/1/1049\">",
"           Prevention of pressure ulcers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/32/10760\">",
"           Treatment of dyslipidemia in the older adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/12/37064\">",
"           Treatment of pressure ulcers",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ophthalmic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/52/6986\">",
"           Age-related macular degeneration: Clinical presentation, etiology, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/29/26074\">",
"           Age-related macular degeneration: Treatment and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/19/2362\">",
"           Cataract in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/59/15289\">",
"           Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/2/34855\">",
"           Open-angle glaucoma: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/11/24754\">",
"           Patient information: Age-related macular degeneration (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/17/2329\">",
"           Visual impairment in adults: Refractive disorders and presbyopia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Physiology of aging",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/52/15178\">",
"           Immune function in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/24/38282\">",
"           Normal aging",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prostate disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/53/36696\">",
"           Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/19/34104\">",
"           Epidemiology and pathogenesis of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/1/11290\">",
"           Lower urinary tract symptoms in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/31/8698\">",
"           Medical treatment of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/51/28467\">",
"           Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/21/15698\">",
"           Patient information: Benign prostatic hyperplasia (enlarged prostate) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/7/40056\">",
"           Surgical and other invasive therapies of benign prostatic hyperplasia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urinary incontinence",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/14/29929\">",
"           Clinical presentation and diagnosis of urinary incontinence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/1/7192\">",
"           Epidemiology, risk factors, and pathogenesis of urinary incontinence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/29/28122\">",
"           Nocturia: Clinical presentation, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/32/1546\">",
"           Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/10/43177\">",
"           Stress urinary incontinence in women: Choosing a primary surgical procedure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/23/44409\">",
"           Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/58/17319\">",
"           Stress urinary incontinence in women: Preoperative evaluation for a primary procedure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/49/33562\">",
"           Stress urinary incontinence in women: Retropubic midurethral slings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/4/32842\">",
"           Treatment of urinary incontinence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/48/41737\">",
"           Urinary incontinence in men",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-08A8158FC0-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f5_58_6063=[""].join("\n");
var outline_f5_58_6063=null;
